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ABSTRACT
HOUSE MAST CELL PROTEASES:
INDUCTION, MOLECULAR CLONING, AND CHARACTERIZATION
By 
Wei Chu
Tryptase, a mast cell-specific serine protease with 
trypsin-like specificity, has been identified in a mouse 
mast cell line (ABFTL-6) based on it's enzymatic activity, 
inhibition properties, and cross-reactivity to a human mast 
cell tryptase antibody.
The effects of fibroblast-conditioned medium and sodium 
butyrate on ABFTL-6 mast cell differentiation and tryptase 
expression have been examined. ABFTL-6 mouse mast cells 
undergo phenotypic changes upon culturing in media 
supplemented with fibroblast-conditioned media at 50% or 1 
mM sodium butyrate. The induced cells increased in size, 
had larger and more metachromatic cytoplasmic granules, and 
increased their total cellular protein about four-fold. 
Tryptase activity increased 13- and 6-fold upon fibroblast- 
conditioned media and butyrate induction, respectively. 
However, tryptase antigen levels increased dramatically from 
2.3 jxg/106 uninduced cells to 125 (54-fold) and 75 (33-fold) 
/ig/10* cells induced with fibroblast-conditioned media or 
butyrate, respectively.
A cDNA library was constructed in JLgtlO from ABFTL-6 
cell poly (A)+ RNA, and screened with dog mast cell tryptase 
and rat mast cell chymase cDNAs. Clones encoding two 
distinct tryptases (mouse tryptases I and II), a chymase 
(mouse chymase I) and a novel carboxyl terminal chymase 
(mouse chymase II) were isolated and sequenced.
Mouse tryptases I and II have 75% and 70% sequence 
identity at the nucleotide and amino acid levels, 
respectively. The deduced amino acid sequence for the 
mature active enzyme for each mouse tryptase contains 245 
residues and all the characteristics of a serine protease. 
Asp is found in the substrate binding pockets, consistent 
with a trypsin-like specificity for Arg-X and Lys-X bonds.
It is predicted that tryptases are synthesized with 
prepropeptides, requiring signal peptidase processing and 
removal of a three amino acid propeptide for activation.
Mouse chymase I consists of a 226 amino acid catalytic 
portion and a 21 amino acid preprosequence. An Asn occurs 
in the substrate binding pocket, a feature that has not been 
observed in any other serine protease.
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CHAPTER 1 
Introduction
Mast cells are wildly distributed throughout the 
mammalian body, predominantly at the host-environment 
interfaces such as the skin, respiratory tract and 
gastrointestinal systems. Mast cells appe&r primarily in 
the mucosa and loose connective tissues. Here they are 
situated most often in the vicinity of blood and lymphatic 
vessels, near or within peripheral nerves, and beneath 
epithelial surfaces that are exposed to environmental 
antigens (Selye, 1965; Metcalfe et al., 1981; Bienenstock et 
al., 1989). Mast cells are best known for their roles in 
the IgE-dependent immediate hypersensitivity reactions and 
the defense against parasitic infection. However, recent 
studies have revealed a considerably greater complexity of 
mast cell biological function than previously had been 
believed to exist (Galli, 1990). Although the precise roles 
of mast cells in health and disease are not fully 
understood, they are believed to have important functions in 
a variety of biological processes. These processes include 
delayed hypersensitivity (Askenase and van Loveren, 1983), 
cytotoxicity (Farram and Nelson, 1980; Henderson et al., 
1981; Ghiara et al., 1985; Capron et al., 1978), immuno- 
regulation (Beer and Rocklin, 1984), fibrosis (Broide et 
al., 1990), and inflammation (Kaliner and Lemanske, 1984).
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Local or systemic increases in mast cell numbers have been 
identified in tissues in a variety of clinical situations 
including inflammation, parasitic infestations (Befus and 
Bienenstock, 1979), rheumatoid arthritis (Athreya et al., 
1979), lymphoproliferative syndromes (Yoo et al., 1978), 
inflammatory bowel disease {Kirsner and Shorter, 1982), and 
atopic dermatitis (Mimh et al., 1976).
Mast cells are immunoglobulin (Ig) E receptor-bearing 
cells. The cross-linkage of these high affinity receptors, 
which results in mast cell degranulation, is central to the 
induction of allergic inflammatory responses. However, mast 
cells can be induced to release their cytoplasmic granules 
by a wide variety of stimuli (Lagunoff and Chi, 1980). Some 
of these mast cell secretagogues are schematically 
summarized in Figure 1. Sensitivity to many of these 
secretagogues varies greatly depending on the mast cell 
type. Also, the extent and nature of mast cell granule 
components released may vary according to the type and 
concentration of stimulus, reflecting differences in mast 
cell activation mechanisms and the potential roles of these 
cells in biological processes not involving Ig E. Thus, the 
common assumption that mast cell activation is an "allergic" 
or IgE-dependent event is far too restrictive.
Upon activation, mast cells secrete a variety of 
preformed, biologically-active mediators stored in 
cytoplasmic granules. These mediators include histamine,
3Chemicals
compound 48/80 
calcium lonophoro 
A23187
Anaphylatoxins
C3a, C4a, COa
Histamine Releasing 
Factors
nautrophil 
eosinophil 
lymphocyte 
macrophago
Allergen Antibody
Mast Cell
I
Degranulation
Neuropeptides
somatostatin 
nourotansln 
neurokinin K 
substance P
Drugs
muscle rclaxants 
opioids
Physical Stimuli
heat
cold
pressure
Figure 1. Schematic illustration of selected mast cell 
secretagogues. This figure was adopted with modifications 
from Friedman and Kaliner (1987).
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proteoglycans, serine proteases, and many chemotactic 
factors. In addition, stimulated cells can synthesize and 
release metabolites of arachidonic acid, such as 
prostaglandins and leukotrienes. Activated mast cells also 
increase messenger RNA (mRNA) synthesis and secretion for a 
group of lymphokines including interleukin-3 (IL-3) (a mast 
cell growth factor), IL-4 (an IgE-switch factor), IL-5 (an 
eosinophil differentiation factor) and IL-6 (a factor 
controlling immunoglobulin secretion) (Plaut et al., 1989). 
These peptide factors may account for much of the 
inflammatory reaction and the late phase allergic reaction. 
They may also participate in the regulation of the mast 
cell's own proliferation and phenotype, especially during 
immunological and pathological processes. Furthermore, 
several laboratories have provided evidence for the presence 
of tumor necrosis factor a-like activities in mast cells.
For example, mast cell cytotoxity and the ability to induce 
endothelial cell production of endothelial-leukocyte 
adhesion molecule 1 have been attributed to tumor necrosis 
factor a located in mast cell granules (Jadus et al., 1986; 
Okuno et al., 1986; Klein et al., 1989). These findings may 
aid in explaining the roles of mast cells in a wide range of 
tissue responses since tumor necrosis factor a has a number 
of biological effects. These include stimulation of 
collagenase and prostaglandin E2 production, stimulation of 
osteoclasts and bone resorption, and enhancement of
eosinophil toxicity (Vilcek et al., 1986; Capron et al., 
1978).
The discovery of mast cells is attributed to Paul 
Ehrlich (1878) who first identified mast cells in human 
connective tissues on the bases of the metachromatic 
staining properties of their prominent cytoplasmic granules. 
Because of the large granules, the cells were originally 
thought to be phagocytic and given the name "mast" which in 
German means "to eat". In the century since their 
discovery, considerable effort has been devoted to 
understanding the biology and function of mast cells. 
Recently, breakthroughs have made possible new and more 
definitive approaches for analyzing the development and 
regulation of mast cell phenotypes and for studying mast 
cell functions. One important achievement was the 
establishment of the mast cell- and hemopoietic stem cell- 
deficient mutant mouse strain WBBGFj-W/W7 (Kitamura et al., 
1978; Kitamura and Go, 1979; Geissler and Russell, 1983). A 
second major development was the generation of rodent mast 
cells in vitro from hematopoietic tissues (Ginsburg, 1963; 
Ginsburg and Lagunoff, 1967). These advancements have 
helped clarify many long-standing issues in mast cell 
biology.
Hast Cell Heterogeneity. Differentiation and Origin
The regulation of mast-cell heterogeneity has attracted 
wide-spread interest. It is believed that mast cells of
different phenotypes may have different roles in health and 
disease. The initial observations that mast cells at 
different histological locations exhibit distinctive 
morphologies were made nearly 100 years ago. Maximow (1905) 
first noticed that certain mast cells in the rat intestinal 
mucosa were atypical in their histochemical staining 
characteristics, differing from mast cells located in other 
tissues. Beginning in the 1960s, EnerbSck (1966a, 1966b, 
1966c, 1981) greatly extended these observations by 
describing the distinctive properties of mast cells in 
connective tissue and in the mucosa of the gastrointestinal 
tract. These results were confirmed by numerous 
investigators (Bienenstock et al., 1982; Shanahan et al., 
1984; Barrett and Metcalfe, 1984). There are two clearly 
distinguishable populations of mast cells characterized in 
rodents based principally on their location and their 
different morphological, immunological, biochemical, and 
functional properties (reviewed by Galli, 1990). The terms 
"mucosal mast cell" and "connective tissue-type mast cells" 
(i.e., MMC and CTMC, respectively) are now the most widely 
accepted designations for rodent mast cell subclasses. The 
heterogeneity of mast cells is best defined in the rat. The 
major phenotypic differences between these two rodent mast 
cell subclasses are listed in Table 1, In comparison with 
the CTMC, the MMC are smaller, have fewer cytoplasmic 
granules, possess a different serine protease composition,
7Table 1. Phenotypic characteristics of mast cell 
populations in the rat*
Characteristics
Location
Size
Granules
Proteoglycan
Serine protease
Histamine
Life span
Histamine release 
by compound 48/80
IL-3 dependency of 
proliferation
Metachomasia with 
formalin fixation
Staining with 
safranin
Staining with 
berberine sulfate
MMC
4
mucosa
9.7 ± 2.2 pm
Few and small
Lower sulfation, 
chondroitin 
sulfate £
RMCP II
< 1 pg/cell
£ 4 0  days
+
+
CTMC
skin, submucosa 
connective tissue
19.6 ± 2.7 pm
Many and large
Higher sulfation, 
heparin
RMCP I 
> 15 pg/cell 
> 4 0  days 
+
+
+
‘Adopted with modification from Bienenstock et al.,
(1982).
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depend on IL-3 for proliferation, and are found most 
prominently in the gastrointestinal tract. In addition, MMC 
contain chondroitin sulfate E glycosaminoglycans rather than 
heparin and have a lower histamine content. MMC are 
nonresponsive to agents such as compound 48/80 and polymyxin 
which degranulate CTMC. Also, MMC differ histochemically 
from CTMC in that MMC can be detected in tissue sections 
only if acidified formaldehyde fixative or Carnoy's fixative 
is used. Both MMC and CTMC stain positive with alcian blue, 
but only CTMC could be stained with safranin (EnerbSck,
1986). Berberine sulfate, a fluorescent dye with an 
affinity to heparin, has been used to distinguish CTMC from 
MMC (Enerback, 1974).
Mammalian mast cells are known to be derived from 
hematopoietic precursors which originated in the bone 
marrow. This was conclusively established in the mouse by 
Kitamura et al. (1978). They demonstrated that mast cell 
deficient WBB6Ft-W/Wv mice can develop both CTMC and MMC 
populations if they receive bone marrow cells from normal 
donor mice. In vitro studies also have confirmed their 
hematopoietic origin. Hasthorpe (1980) and others (Nagao et 
al., 1981; Razin et al., 1981; Schrader, 1981; Tertian et 
al., 1981) discovered that apparently pure mast cell 
populations could be generated by culturing cells from 
normal rodent hematopoietic tissues such as bone marrow, 
spleen, lymph node, or fetal liver in media containing IL-3.
Nakano et al. (1985) have shown that in vitro-cultured, 
IL-3-dependent mouse bone marrow-derived mast cells (BMMC) 
can give rise to both CTMC and MMC because both populations 
are reconstituted in W/Wv mice by the transplantation of IL- 
3-dependant BMMC. This observation suggests that both MMC 
and CTMC populations are derived from a common precursor 
cell.
Human mast cells also exhibit variation in multiple 
aspects of their phenotype, including the content of 
granule-associated serine proteases, cytoplasmic granule 
ultrastructure, histochemical properties, quantity of stored 
histamine, and sensitivity to stimulation by various 
secretogogues and drugs. Like rat mast cells, human mast 
cell subclasses also differ in serine protease content, 
which distinguish human mast cell subclasses. Some human 
mast cells contain both tryptase and chymase (designated as 
TC mast cells), whereas other human mast cells contain 
tryptase but no detectable chymase (designated as T mast 
cells) (Irani et al., 1986). TC and T mast cells appear 
analogous in some respects, but not all, to rodent CTMC and 
MMC, respectively. Unlike rodent mast cells, human mast 
cells can not be classified based on tissue location alone.
T mast cells predominate in the lung and small intestinal 
mucosa; TC mast cells predominate in skin and small 
intestinal submucosa. However, these anatomical sites
10
contain representatives of both mast cell subtypes 
(Schwartz, 1989).
Micro-environmental Regulation of Mast Cell 
Development and Phenotype
It is well established that rodent mast cells could be 
generated in vitro by culturing cells from hemopoietic 
tissues in the presence of IL-3 (Nakahata et al., 1986). 
These in vitro-derived. IL-3-dependent mast cells have been 
cloned, and many cell lines have been established. Thus, 
these cells can be obtained in large quantities, providing a 
good source of mast cells for a variety of biochemical and 
functional studies. This approach usually results in the 
generation of basophils in humans rather than mast cells; 
however, a recent report indicates that it is possible to 
generate mast cell-like cells from human bone marrow under 
certain culture conditions (Kirshenbaum et al., 1989). 
Reasons for such difference among species are not clear.
These in vitro-differentiated, IL-3-dependent mast 
cells are considered as the in vitro counterpart of the in 
vivo-differentiated MMC, as assessed by ultrastructure, 
histochemical staining, and IL-3 dependency for 
proliferation. Similar to MMC, mast cells derived from 
hemopoietic tissues contain fewer granules which stain 
alcian blue+/safrain‘, synthesis lower levels of histamine, 
and chondroitin sulfate E proteoglycans rather than heparin 
(sredni et al., 1983; Razin et al., 1982). Moreover, rat
11
BMMC carry rat mast cell protease II {RMCP II) which is 
specifically expressed in rat MMC (Haig et al., 1982, 19B6).
As discussed in the previous section, IL-3 dependent 
BMMC populations whose phenotype resembles that of MMC give 
rise to both CTMC and MMC populations in different 
anatomical sites of W/Wv recipients. This result suggests 
that different mast cell subclasses are derived from cells 
of a single lineage, and also that BMMC can undergo the 
phenotypic change from MMC-like to CTMC; this was later 
confirmed by biochemical characterization (Otsu et al.,
1987). Similar findings were obtained with peritoneal mast 
cells, a classical example of CTMC, which could give rise to 
mast cells phenotypically similar to either the CTMC or MMC 
(a CTMC MMC-like change) (Nakano et al., 1987). Thus, it 
appears that the tissue micro-environment determines the 
phenotypic characteristics of mast cells.
In vitro it was demonstrated that by co-culturing with 
a 3T3 fibroblast monolayer, BMMC could be induced to 
differentiate and undergo phenotypic changes to resemble 
CTMC. The co-cultured mast cells increase their content of 
cellular granules, which stain with safranin, raise their 
histamine content 50-fold and carboxypeptidase A 100-fold, 
and initiate the synthesis of heparin proteoglycans (Levi- 
Shaffer et al., 1986; Dayton et al., 1988). Also, sodium 
butyrate increases BMMC cytoplasmic granule-associated 
serine protease levels 4-fold and histamine content 10-fold
12
(DuBuske et al., 1984). The sodium butyrate-treated mast 
cells, however, remained alcian blue+/safranin', and did not 
synthesize detectable quantities of heparin (Galli et al., 
1982). Sodium butyrate is a pharmacologic agent that causes 
hypermethylation and acetylation of cellular histones and 
differential expression of mRNA (Riggs et al., 1977). 
Dexamethasone has been found to have a similar effect on 
BMMC (Pitton et al., 1988).
Xn vivo and in vitro studies have confirmed that mast 
cells can change phenotype from "MMC CTMC-like" and "CTMC 
-+ MMC-like". Recent evidence using cloned mast cell 
populations indicate that at least some of these changes are 
reversible (i.e. "MMC -* CTMC-like -* MMC» or "CTMC -♦ MMC-like 
CTMC") upon changes of the micro-environment (Kanakura et 
al., 1988). It seems likely that T-lymphocyte factors (i.e. 
IL-3) are needed to induce progenitor cells to differentiate 
and proliferate along the mast cell lineage. However, the 
subsequent micro-environment which the mast cells settle 
into determines their final phenotypic properties. This 
scheme is illustrated in Figure 2.
Mast Cell Granule-Associated Serine Proteases: 
Trvotase and Chvmase 
One characteristic feature of mast cells is the 
presence of high levels of proteolytic enzymes in the 
secretion granules. These granules are known to contain 
proteases with both trypsin-like and chymotrypsin-like
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Figure 2. Schematic diagram of rodent mast cell development 
and differentiation, circulating mast cells are derived 
from precursor cells originating from bone marrow. Further 
differentiation of precursor cells into mature mast cells is 
under the influence of the microenviroment where the 
precursor cells settle. The mature mast cells (CTMC and 
MMC) are not end-staged cells and are able to undergo 
further phenotypic changes if the tissue microenviroment or 
culture conditions change.
specificities, referred to as tryptase and chymase, 
respectively. Both enzymes are exclusively expressed in 
mast cells. Tryptase and chymase are stored in fully active 
form in association with acidic proteoglycans, mainly 
heparin, within the cytoplasmic granules. They are secreted 
with other preformed mediators upon the coupled activation- 
degranulation response of mast cells (Schwartz et al.,
1981b; Caughey et al., 1988b). This secretion process 
differs from that for trypsin and chymotrypsin, which are 
stored in pancreatic acinar cell granules as inactive 
trypsinogen and chymotrypsinogen zymogens, respectively, and 
are proteolytically activated after their release.
The serine proteases comprise a large group of enzymes 
which are characterized by possessing a catalytic charge 
relay system, including a reactive serine residue in the 
active site. They are also known as neutral protease since 
they are most active in the physiological pH range. The 
distinguishing feature of these enzymes is their 
susceptibility to inhibition by interaction of the active 
site serine with diisopropylfluorophosphate (DFP). This 
group of enzymes (represented by trypsin, chymotrypsin, and 
elastase) are classified as endopeptidases and cleave 
peptide bonds on the carboxyl side of preferred amino acid 
residues which define the enzyme’s substrate specificity.
Benditt and Arase (1959) first detected a protease with 
a chymotryptic activity, now called RMCP I, in CTMC isolated
from the peritoneal cavity of rats. Later, a second 
chymotryptic protease designated as RMCP IX was localized 
exclusively in rat MMC (Woodbury et al., 1978). RMCP I and 
RMCP II have substantial amino acid sequence homology with 
one another (Benfey et al., 1987; Woodbury et al., 1978) but 
are distinct gene products that can be distinguished from 
one another with polyclonal antibodies. A complementary DNA 
(cDNA) that encodes RMCP II and its corresponding genomic 
clone have been isolated (Benfey et al., 1987). This work 
also provided evidence that RMCP II is synthesized as a 
precursor molecule, with an amino terminus signal peptide 
and additional residues at the carboxyl terminus.
Mast cell chymases from several other species, 
including mouse (Le Trong et al., 1989), dog (Caughey et 
al., 1988b; Schechter et al., 1988), sheep (Huntley et al., 
1986), and human (Schechter et al., 1983, 1986; Wintroub et 
al., 1986; Sayama et al., 1987), have been isolated and 
partially characterized.
Glenner and Cohen (i960) first discovered high levels 
of intracellular tryptic activity in mast cells by enzyme 
histochemical staining. Since then, similar enzymes have 
been isolated and characterized from human (Schwartz et al,, 
1981a; Smith et al., 1984; Cromlish et al., 1987; Harvima et 
al., 1988; Butterfield et al., 1990), dog (Caughey et al., 
1987; schechter et al., 1988) and rat (Kido et al., 1985) 
mast cells or mast cell-rich tissues. While chymase is the
major granule-associated serine protease of rat mast cells, 
tryptase seems to be the predominant protein component of 
human mast cells. Tryptase is estimated to comprise as much 
as 23% of mast cell total protein (Schwartz et al., 1981b). 
Tryptase polypeptides appear heterogenous on SDS- 
polyacrylamide gel electrophoresis (SDS-PAGE) with two major 
bands of Hr = 30,900 and 31,600 (smith et al., 1984). The 
active enzymes appear to exist as tetramers of subunits with 
a Mr = 135,000 (Schwartz et al., 1981a; Cromlish et al., 
1987; Caughey et al., 1987; Harvima et al., 1988; Kido et 
al., 1988). The observed electrophoretic heterogeneity 
seems to be due in part to differences in glycosylation 
(Cromlish et al., 1987), but differences in primary 
structure can not be ruled out. The recent report of 
multiple tryptase cDNAs in human mast cells supports the 
latter hypothesis. Functional heterogeneity has been 
observed regarding the specificities of human lung and skin 
tryptases toward synthetic substrates (Tanaka et al., 1983). 
Tryptase is stabilized and possibly regulated by the binding 
of heparin which also resides in secretory granules. The 
affinity of human mast cell tryptase for heparin has been 
used as a purification step (Schwartz et al., 1981a) and 
differences in this property were used to partially separate 
the two predominant forms of human lung tryptase (Smith et 
al., 1984).
Tryptase has a trypsin-like substrate specificity, and 
therefore hydrolyses peptide bonds on the carboxyl terminal 
side of the basic residues Arg and Lys. But unlike trypsin, 
tryptase has a marked subsite preference and a 
correspondingly high degree of substrate selectivity (Tanaka 
et al., 1983). These enzymes seem to make only selective 
cleavages in protein substrates and have little if any 
activity against denatured protein substrates such as 
casein. Another characteristic feature of human and dog 
tryptases is resistance to inhibition by plasma serine 
protease inhibitors, such as a-l-proteinase inhibitor (a-1- 
Pl) (Smith et al., 1984; Caughey et al., 1987; Alter et al., 
1990). This feature may not be shared by rat mast cell 
tryptase (Kido et al., 1985). In rat, tryptase is 
associated with and, therefore, may be regulated by an 
endogenous tryptase inhibitor, which has been called 
trypstatin (Kido et al., 1985, 1988).
The presence of high levels of tryptase and chymase in 
mast cells suggests that this enzyme must be an important 
component of mast cell function. The biological roles of 
tryptase remain to be defined. In vitro, human tryptase 
cleaves C3 to generate biologically active C3a (Schwartz et 
al., 1983), destroys high molecular weight kininogen (Maier 
et al., 1983), and inactivates fibrinogen as a coagulable 
substrate for thrombin (Schwartz et al., 1985). Increased 
numbers of mast cells have been found in arthritic joints
(Malone et al., 1986), and, because trypsin is known to 
activate collagenase, it was suspected that tryptase might 
also. Although tryptase failed to activate very pure 
preparations of procollagenase (Johnson and Cawston, 1985), 
Gruber et al. (1988) reported findings to the contrary, 
subsequently, it was found that tryptase activates 
prostromalysin but not procollagenase and the stromalysin, 
which is often a contaminant of procollagenase preparations 
actually activates procollagenase to collagenase. More 
recent studies indicate that tryptase rapidly hydrolyzes 
vasoactive intestinal peptide (Caughey et al., 1988a; 
Franconi et al., 1989), a neuropeptide that relaxes airway 
smooth muscle (Said, 1984), and calcitonin gene-related 
peptide, which is a potent vasodilator and 
bronchoconstrictor. The latter findings may suggest a 
possible role for tryptase in modulating the biological 
effects of neuropeptides.
In vitro, chymase converts angiotensin I to angiotensin 
XI (Wintroub et al., 1984) and cleaves and inactivates both 
substance P and vasoactive intestinal peptide (Caughey et 
al., 1988a). Chymase is able to degrade type IV collagen 
and basement membrane components at the dermal-epidermal 
junction and facilitate separation of these cutaneous 
regions (Briggaman et al., 1984; Sage et al., 1979). In 
addition, chymase inhibitors and antibodies against chymase 
prevent histamine release from stimulated mast cells,
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suggesting that chymase may be involved in certain processes 
triggering mast cell degranulation (Kido et al., 1988;
Dietze et al., 1990).
The first primary structure data of tryptase resulted 
from the cloning and sequencing of a cDNA from a dog 
mastocytoma cell line (Vanderslice et al., 1989). This work 
also resulted in the cloning of a related enzyme's cDNA, 
termed dog mast cell protease, which is 53.4% homologous 
with dog tryptase. Both enzymes appear to share a novel 
activation mode, requiring cleavage at a Gly residue prior 
to the Ile-Val-Gly-Gly amino terminus normal for active 
serine proteases. Subsequently, a human tryptase cDNA, 
which had 84% amino acid sequence identity with dog 
tryptase, was isolated from lung mast cells (Miller et al., 
1989). More recently, three different but highly related 
tryptase cDNAs from human skin and a gene coding for one of 
the skin tryptase cDNAs have been isolated and characterized 
(Vanderslice et al., 1990).
Rat mast cell proteases I and IX are used as selective 
markers for distinguishing rat CTMC and MMC populations, 
respectively. While most mast cell granule-associated 
mediators can be produced by other cell types, the serine 
proteases may represent constituents restricted to the mast 
cells. Thus, they may provide important insights into the 
unique functions of these cells. Also, elevated levels of 
tryptase or chymase in serum or other biological fluids may
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serve as clinically useful indicators of mast cell 
activation and degranulation.
Although little is known concerning mouse tryptase, 
there have been several reports dealing with chymases in 
mouse mast cells. It has been shown that serine proteases 
comprise the major protein components of mouse BMMC 
secretory granules and four granule-associated, [3H] DFP- 
binding proteins, ranging in molecular weight from 27 to 31 
KDa, were identified (Dubuske et al., 1984). These proteins 
were secreted along with other granule-associated mediators 
during mast cell activation (Serafin et al., 1986). The 
first mouse mast cell protease isolated, a chymase 
designated as mouse mast cell protease I (MMCP-l), was from 
the small intestine of mice infected with Trichinella 
spiralis. Its amino acid sequence has been determined 
(Newlands et al., 1987; Le Trong et al., 1989). In 
addition, a second chymase, designated as mouse mast cell 
protease II (MMCP-2), has been identified, and its cDNA has 
been cloned and characterized from Kirsten sarcoma virus- 
immortalized mouse mast cells (Serafin et al., 1990). MMCP- 
2 has 65% amino acid sequence identity to MMCP-l. Similar 
to RMCP II, cDNA sequence data predict that MMCP-2 is 
synthesized as a preproenzyme which contains a 19-amino acid 
hydrophobic signal peptide and a two-amino acid propeptide. 
More recently, four additional distinct serine proteases 
have been identified in mouse serosal mast cells, and their
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amino-terminal amino acid sequences have been reported 
(Reynolds et al., 1990). These data indicate that different 
mouse mast cell subclasses can express various combinations 
of at least six distinct serine proteases.
Preliminary data from enzymatic activity assays and 
immuno-dot blot experiments indicated that mouse tongue and 
lung tissues and the in vitro-derived ABFTL-6 mouse mast 
cells contained tryptase-like enzyme (Pierce et al., 1985). 
Positive immunological cross-reactions were observed with 
antibodies to human mast cell tryptase, and both mouse 
tissues and ABFTL-6 cell lysates were found to contain 
tryptase activity (Chu and Smith, unpublished observations).
To gain insight into mast cell functions in health and 
disease, it is important to understand the regulation of 
mast cell development and differentiation. It is also 
necessary to clarify and understand the nature of the 
granule-associated proteases. In this study, a tryptase 
activity in the ABFTL-6 mouse mast cell line has been 
identified. The effects of fibroblast-conditioned media 
(FCM) and sodium butyrate on cell differentiation and 
tryptase expression in the ABFTL-6 mast cells were examined. 
In addition, cDNAs for two distinct tryptases and two 
chymases from ABFTL-6 cells have been successfully cloned, 
characterized, and sequenced. This work should provide 
reagents for studying the expression and regulation
of these enzyme classes. Also, It is now possible to 
explore the relationship(s) between the primary structures 
and the unique properties of these important proteases in 
mouse mast cells.
CHAPTER 2 
Materials and Methods
MsltqKJLaJls
RFMX 1640; penicillin/streptomycin; sodium butyrate; 5- 
bromo-4-chloro-3-indolyl phosphate (BCIP); CBZ-Lys- 
thiobenzyl ester (Z-Lys-SBzl); tosyl-L-Lys-chloromethyl 
ketone (TLCK); tosyl-L-Phe-chloromethyl ketone (TPCK); lima 
bean trypsin inhibitor (LBTI); benzamidine; antipain; 
phenyl-methanesulfonyl fluoride (PMSF); 5,5'-dithiobis(2- 
nitrobenzonic acid) (Nbs2) ; Tween-20; sodium dodecylsulfate 
(SDS); Coomassie Brilliant Blue G-250; dithiothreitol (DTT); 
N,N,N'/H ,-tetramethylethylenediamine (TEMED); Tris- 
(hydroxymethyl) aminomethane (Tris); IJ-(N-morphoinol) ethane 
sulfonic acid (MES); B-mercaptoethanol (BME); ribonuclease 
(RNase) A; protease K; formamide; and ethidium bromide (EBr) 
were purchased from Sigma Chemical Company. 
Ethylenediaminetetraacetic acid (EDTA), ammonium sulfate, 
urea, nitro BT, acrylamide, polyethylene glycol 8000 (PEG), 
guanidine isothiocyanate (GTC), bovine serum albumin (BSA), 
nitro blue tetrazolium (NBT), 4-(2-hydroxyethyl)-1- 
piperazineethanesulfonic acid (HEPES), toluidine blue, and 
safranin were purchased from Fisher Scientific.
Diisopropylfluorophosphate was a product of Aldrich Chemical 
Company. Bactoagar, bactotryptone, and yeast extract were 
purchased from Difco Laboratories. Fetal bovine serum (FBS)
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was obtained from GIBCO Laboratories. [3H] diisopropyl- 
fluorophosphate, deoxycytidine [a-3ZP] 5'-triphosphate, and 
deoxyadenosine [a-3SS] 5'-triphosphate were purchased from 
New England Nuclear. Adenosine [y-32P] triphosphate was 
obtained from 1CN Chemicals. M13 reverse sequencing primer 
(17-mer) and the cDNA synthesis kit were purchased from 
Pharmacia. Seguenase DNA sequencing kit was from United 
States Biochemical Corporation. Polynucleotide kinase from 
T4, T4 DNA ligase, calf intestinal alkaline phosphatase 
(CIAP), reverse transcriptase, and reagents for primer 
extension were obtained from Promega. The nick translation 
reagent kit was purchased from Bethesda Research 
Laboratories. A random primer DNA labeling kit was 
purchased from Boehringer Mannheim. Lambda in vitro 
packaging extract and predigested lambda gtio DNA/EcoRl 
cloning kit were purchased from Stratagene. Alkaline 
phosphatase-conjugated goat anti-rabbit IgG was from Bio- 
Rad. Nitrocellulose membrane (sheet and disc, 0.22 micron) 
was purchased from Schleicher and Schuell. Agarose was 
purchased from the Marine Colloids Division of the FMC 
Corporation. The prestained standards were products of 
Diversified Biotech.
A mouse mast cell line, ABFTL-6, was a generous gift of 
Dr. Jacalyn Pierce (National Institutes of Health, Bethesda, 
MD). A contact inhibited, Swiss-albino mouse embryo-derived 
3T3 fibroblast cell line was obtained from American Type
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Culture Collection (ATCC # CCL 92). A dog mast cell 
tryptase cDNA clone and a rat mast cell protease XI cDNA 
clone were kindly provided by Dr. Peter Vanderslice (Univ. 
of Calif. San Francisco) and Dr. Philip Leder (Harvard 
Medical School), respectively. Mouse tryptase II 
oligonucleotide was kindly synthesized by Dr. Kent Lohman 
(Southwest Foundation for Biomedical Research, San Antonio, 
TX).
Mouse tissue poly(A)+ RNAs, human tryptase, tryptase 
antibody, and a-l-PI were provided by Dr. David Johnson. 
Mouse genomic DNA and chicken a-tubulin cDNA were supplied 
by Dr. Phillip Musich.
The composition of solutions and buffers used in this 
study and their abbreviations are listed in Appendix I.
Methods
Growth of ABFTL-6 Mast Cells and 3T3 Cells
Both ABFTL-6 mouse mast cells and the 3T3 fibroblasts 
were cultured in RPMI 1640 media supplemented with 10% 
heated-inactivated FBS, 100 unit/ml penicillin and 100 jug/ml 
streptomycin. All cell cultures were maintained at 37°C in 
a humidified atmosphere of 5% C02.
Preparation of FCM
After the 3T3 cells formed a confluent monolayer, the 
culture supernatant was collected by centrifugation at 1,000 
x g for ten minutes. The cell-free supernatant was
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carefully aspirated off and used immediately as FCM in 
ABFTL-6 cell induction experiments. Then, fresh culture 
media was added to the 3T3 cell culture flask to cover the 
cell monolayer (i.e. 50 ml for a T-150 flask). FCM was 
prepared every other day for each culture.
Growth of Mast Cells in 3T3 FCM Supplemented Media
ABFTL-6 cells were grown to a density of 0.5-0.6 x 10fi 
cells/ml. Then, the normal culture media was replaced with 
1:1 mixture of fresh RPMI 1640 media and 3T3 FCM. This 
.culture was maintained for up to 12 days with media being 
changed every other day. Cells stopped dividing in the 
presence of 3T3 FCM.
Sodium Butvrate Treatment of Mast Cells
ABFTL-6 cells at 0.3-0.4 x 104 cells/ml, were treated 
with sodium butyrate by diluting a 100 mM sodium butyrate 
stock solution to a final concentration of 1 mM in fresh 
culture media. This culture was maintained for 4 days with 
daily replacement of the butyrate-supplemented medium.
Histochemical Staining
For metachromatic staining, ABFTL-6 cells were 
collected by centrifugation at 100 x g and washed with PBS 
buffer once in a 1.5 ml microfuge tube. The cells were 
suspended in 300 pi of Zamboni fixative solution (Stefanini 
et al., 1967) for 1-3 minutes, pelleted by centrifugation 
and stained in 300 pi of 0.5% (w/v) tpluidine blue in 0.5 N
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HC1 for 30-60 minutes. The stained cells were washed twice 
with deionized water (dH20), smeared, and air dried on 
microscope slides for microscopic examination.
Alcian blue staining with a safranin counterstain was 
performed as described (Ishizaka et al., 1976). The mast 
cells1 pellets were smeared, air dried on microscope slides, 
and stained for 5 minutes in 0.5% alcian blue in 0.3% acetic 
acid. After rinsing with dH2o, the cells were counter­
stained with 0.1% safranin in 1% acetic acid for 5 minutes.
Preparation of Hast Cell Extracts
cultured cells were harvested by centrifugation at 100 
x g for 5 minutes. The cells were washed with phosphate- 
buffered saline (PBS) and resuspended in an appropriate 
volume (usually at 20 x 10s cells/ml) of 10 mM MES buffer, 
pH 6.1, containing 2 M NaCl. The cell suspension was frozen 
immediately in a dry ice-ethanol bath, and the cells were 
lysed by repeated thawing and freezing four times, resulting 
in complete lysis as judged by trypan blue exclusion. The 
extract was clarified by centrifugation in a microfuge at
12,000 x g for 10 minutes to remove insoluble cell debris.
Determination of Protein Concentration
The protein concentration of the cell extract was 
determined by the method of Bradford (1976). Three ml of 
Bradford reagent was added to 0.1 ml TBS buffer containing 
10-50 )Ltl of cell extract and mixed by vortexing. The
28
absorbance at 595 nm was measured in a 1 ml cuvette against 
a reagent blank prepared from 0.1 ml TBS buffer and 3 ml of 
Bradford reagent. Dilutions of a 1 mg/ml BSA solution, 
prepared based on a 280 nm extinction coefficient for 1% 
protein solution of 6.6, were used to construct a standard 
curve to determine the protein concentration in unknown 
samples.
Measurement of Enzymatic Activity
Tryptic activity was determined by hydrolysis of the 
chromogenic substrate Z-Lys-SBzl. one unit of activity was 
defined as that amount of enzyme resulting in an absorbance 
at 410 nm increase of one absorbance unit per minute when 
the initial rate was linear. Reactions were carried out at 
room temperature in a 1 ml volume containing 10-50 (tl of 
cell extract, 0.1 mM Z-Lys-SBzl, 0.65 mM DTNB, 0.15 M NaCl, 
0.05% Brij-35, and 0.1 M HEPES, pH 7.5. The rates of 
absorbance increase were measured with a Beckman Model 35 
Spectrophotometer.
Inhibition of Tryptic Activity Assay
The effects of various serine protease inhibitors on 
the tryptic activity in the mast cell extracts were tested 
by preincubating 10 fil of extract with each of the 
inhibitors for 60 minutes at room temperature. For protease 
inhibitors TLCK (1 mg/ml), TPCK (1 mg/ml), benzamidine 
(2 mM), and antipain (0.1 mg/ml), the preincubation volume
was 400 III; FMSF (2 mM), a-l-PI (0.1 mg/ml), DFP (2.7 mM), 
and LBTI (o.l mg/ml) were preincubated in a volume of 100 
/zl. The concentration of inhibitors indicated in 
parentheses were the final concentration in the 
preincubation mixture. The tryptic activity remaining after 
a 60 minute preincubation period was measured by following 
the hydrolysis of Z-Lys-SBzl in a 1 ml reaction as described 
above. Residual activity was expressed as a percentage of 
similarly incubated controls containing the same amount of 
cell lysate, but no inhibitors. The control values were set 
at 100% activity.
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Protein samples were precipitated with 20% 
trichloroacetic acid (TCA) at 4°C for 30 minutes. The 
protein precipitate was collected by centrifugation for 15 
minutes in a microfuge (12,000 x g) at 4°C, washed 
sequentially with cold 10% TCA and twice with 100% acetone, 
and air dried. The protein pellets were resuspended in 
25-50 fil sample buffer and boiled for 3 minutes to denature 
proteins. Electrophoresis was performed using a Bio-Rad 
Model 360 slab gel electrophoresis apparatus and the amidiol 
buffer system of Bury (1981). Proteins were separated on a 
10% SDS-polyacrylamide gel (acrylamide/bis : 19/1). 
Electrophoresis was carried out at a constant current of 
15 mA in the stacking gel and 20 mA through the resolving 
gel until the bromphenol blue dye front ran off the bottom
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of the gel. Following electrophoresis, gels were stained 
with Coomassie Brilliant Blue G-250 by the method of Steck 
et al. (1980) and destained with a solution containing 
methanol, water, and acetic acid at a ratio of 5:5:1.
r3Hl DFP Labeling of Serine Proteases and Fluoroqraphv 
Cell extracts equivalent to 0.7 x 106 cells were 
incubated with 45 (id [3H] DFP in a volume of 200 fil for 
60 minutes at 22°C. The labeled proteins were then 
precipitated with 20% TCA at 4°C for 30 minutes and prepared 
for SDS-polyacrylamide gel electrophoresis (SDS-PAGE).
After electrophoresis, the gel was soaked in 1 M sodium 
salicylate for 30 minutes and dried on Whatman 3 MM paper 
under vacuum before autoradiographing at -70°C using Kodak 
X-AR film.
In another experiment, the lysates were incubated with 
an excess of TPCK, which is known to inhibit chymotrypsin, 
but not trypsin, for 60 minutes prior to incubation with 
[3H] DFP. Thus, the binding of [3h ] DFP to chymotryptic 
proteases was presumably blocked, resulting in the 
preferential labeling of other serine proteases.
Immuno-dot and Western Blotting
Immuno-dot blots were accomplished as described by 
Smith et al. (1989) using the Bio-Rad Bio-Dot 96 well 
filtration apparatus. Cell extracts were diluted, and an 
amount of extract equivalent to a fixed number of cells was
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applied to a nitrocellulose membrane by gravity filtration. 
Each well was then washed with 200 pil TBS by vacuum 
filtration. For Western blots, proteins separated by SDS- 
PAGE were blotted onto a nitrocellulose membrane using a 
Milliblot-SDS system (Millipore) according to the 
manufacture's instruction.
The membranes were blocked with 3% BSA £w/v) in TBS for 
4 hrs and incubated with a 500-fold dilution of a rabbit 
antisera to human mast cell tryptase in TBS containing 
3% BSA and 0.05% Tween-20, usually for overnight. After 
washing the membranes three times for 10 minutes each in TBS 
containing 0.1% Tween-20, they were incubated for 6 hours 
with a 2000-fold dilution of the alkaline phosphatase- 
conjugated goat anti-rabbit IgG secondary antibody. The 
membranes were developed in carbonate buffer (0.1 M NaHC03,
1.0 mM MgCl2, pH 9.8) containing o.is mg/ml BCIF and 0.3 
mg/ml NBT with gentle shaking. After the appropriate 
intensity of the color developed, the reaction was stopped 
by rinsing the filter with water.
F o l v m 4—HNA Isolation
This is the first step for cDNA cloning of mouse mast 
cell proteases. The procedure for molecular cloning are 
outlined in Figure 3. Total RNA was isolated using the 
GTC/Csd density gradient centrifugation method of Chirgwin 
et al. (1979). Frozen cell pellets of uninduced ABFTL-6 
cells (1.7 x 10a cells) were suspended in 9 ml of 5.5 M GTC
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Figure 3. Outline of the procedure for cloning the cDNA 
for mouse mast cell tryptases and chymases. Cultured ABFTL- 
6 mast cells were used as the source for poly(A)+ RNA. A 
cDNA library was constructed in AgtlO from the ABFTL-6 
poly(A)+ RNA and screened for tryptases or chymase by plaque 
hybridization with dog tryptase or rat chymase cDNA as 
probes, respectively. The recombinant DNA of positive 
clones was isolated and characterized by restriction 
cleavage analysis. The inserts and their restricted 
subfragments were subcloned into pTZ19U plasmid for 
sequencing.
buffer to lyse the cells, followed by passage though an 18 
gauge needle (approximately 6 times) attached to,a 10 ml 
syringe until the viscosity decreased due to shearing of the 
DNA. The lysate was centrifuged at 5000 x g for 10 minutes 
at 4°C to remove cell debris, then one half of the 
supernatant was layered over 2 ml of 5.7 M CsCl in each of 
two 13 ml tubes. The RNA was pelleted by centrifugation in 
a Du Pont AH650 swinging bucket rotor for 24 hours at 35,000 
rpm at 18°c. After centrifugation, the liquid in each tube 
was carefully removed by aspiration, followed by inversion 
and draining on a paper towel for 5 minutes. The RNA pellet 
was redissolved in 2 ml solution containing 0.5 mM EDTA,
0.5% sodium lauryl sarcosinate, and 5% BME and extracted 
sequentially with phenol/chloroform (1:1) and chloroform.
The RNA was precipitated twice with ethanol and stored at 
-80°C as a dried pellet.
The poly (A)* RNA was purified from total RNA by two 
cycles of chromatography on oligo(dT)-cellulose (Aviv and 
Leder, 1972). After washing sequentially with a 0.1 N 
NaOH/5 mM EDTA solution and water, the oligo(dT)-column was 
equilibrated with loading buffer (20 mM Tris-HCl pH 7.6, 0.5 
M LiCl, 1 mM EDTA, 0.1 % sodium lauryl sarcosinate). The RNA 
sample was dissolved in RNase-free HzO, heated at 65°C for 
5 minutes, and mixed with one volume of twice-concentrated 
loading buffer before application to the column. Then, the 
column was washed sequentially with loading buffer and low
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salt buffer (same as loading buffer except containing 0.1 M 
NaCl instead of 0.5 M LiCl) until the absorbance at 260 nm 
of the eluent reached zero with each buffer. The poly(A)+ 
RNA was eluted with 10 mM Tris-HCl pH 7.6, 1 mM EDTA, 0.05% 
SDS. The low salt wash and the eluted poly(A)+ fractions 
were combined and rechromatographed on the column. After 
elution, the poly(A)+ RNA containing fractions, based on the 
absorbance at 280 nm, were ethanol precipitated.
cDNA Synthesis and Library Construction
Double-stranded cDNA was synthesized from the mouse 
mast cell poly (A)+ RNA by the method of Gubler and Hoffman 
(1983), and a cDNA library was constructed in AgtlO from the 
cDNA as described by Hyunh et al. (1985). The cDNA library 
was prepared using the Pharmacia cDNA Synthesis Kit and the 
Stratagene AgtlO Cloning Kit and Gigapack Packaging Extract; 
the manufacturers' instructions were followed. A schematic 
diagram for cDNA synthesis is shown in Figure 4. Briefly, 
poly (A)+ RNA (4 fig) was primed with oligo <3(T)12.ie which was 
extended with reverse transcriptase to synthesize the first 
strand. The RNA-cDNA duplex was partially hydrolyzed with 
RNase H, and the resulting nicked RNA was used to prime 
second-strand synthesis employing E. coli DNA polymerase I. 
The double-stranded cDNA mix was extracted with 
phenol/chloroform, made blunt-ended by fill-in synthesis 
with Klenow fragment DNA polymerase, and then size-selected 
using a Sephacryl S-3 00 spin column with a 260 bp void
35
mRNA
mRNA: cDNA 
duplex
Double-  
stranded cDNA
E coR I-ended ___
cDNA ' EH li
3’
po!y(A)
IRovorso transcriptaso dNTPs, Oligo(dT)
DNA polymerase I 
RNaso H, dNTPs 
Klonow fragment 
Size soloction
I T4 DNA ligaso, HcoRl/Notl adaptors Kinaso, ATP
I
Ugato into EcoRI -  cleaved 
Lambda gt10 vector
Figure 4. Schematic diagram of cDNA synthesis. cDNA was 
synthesized by the method of Gubler and Hoffman (1983), 
using a cDNA synthesis kit from Pharmacia. See text for 
details.
exclusion limit. Following attachment of an EcoRI/Notl 
linker, the cDNA was phosphorylated with T4 polynucleotide 
kinase and extracted with phenol/chloroform. The free 
linkers were removed using another Sephacryl S-300 spin 
column. Then the cDNA was ligated to EcoRI pre-cleaved, 
undephosphorylated AgtlO DNA in a 5 |il reaction volume. One 
raicroliter of the ligation mix was packaged in vitro with 
intact A phage particles, resulting in a cDNA library 
containing 2 x 106 independent recombinants. The titer of 
the recombinant phage in the unamplified library was 4600 
pfu//xl.
cDNA Library Screening
The unamplified cDNA library was screened by 
hybridization of plaque lifts to a dog mast cell tryptase 
(Vanderslice et al., 1989) or a rat chymase cDNA (Benfey et 
al., 1987). All probes were labeled with a3ZP-dCTP by the 
random priming method (Feinberg and Vogelstein, 1984). The 
recombinant phage were propagated in Escherichia coli (E. 
coli) C600 Hfl for first round screening to eliminate 
background of wild type lambda phage, and in C600 for 
subsequent screening, one single colony of host cells from 
a NZY agar plate was inoculated into SO ml TB broth 
containing 0.2% maltose and 10 mM MgSO^. The culture was 
incubated overnight with shaking at 37°C. The cells were 
pelleted at 1,000 x g for 10 minutes and gently resuspended 
in 10 ml of 10 mM MgSO^. The library was initially screened
at a density of 2 X 104 plaques/ 150-mm plate. Plaques were 
lifted onto nitrocellulose filters, denatured in 0.5 N 
NaOH/1.5 M NaCl and neutralized in 1 M Tris-HCl, pH 7.0, 1.5 
M NaCl. The filters were baked at 80°C for 30 minutes in a 
vacuum oven. Hybridizations at standard stringency were 
carried out in 3 X s s c , 10 mM Tris-HCl (pH 7.4), 50% 
formamide, 1% nonfat dry milk, and 0.1% SDS at 42°C for 12- 
16 hours, standard stringency hybridizations allowed for 
29% mismatch with a probe containing 68% G + C (McCanaughy 
et al., 1969). After hybridization, the filters were washed 
3 times for 30 minutes in 3 X SSC/0.1% SDS at 65°C.
Positive recombinants were detected by overnight 
autoradiography at **70°C using Kodak XAR film with two Du 
Pont Cronex Lightning Plus intensifying screens and isolated 
by repeated cycles of plaque purification. Recombinant 
phage DNA was obtained as described below and slot-blotted 
onto a Nytran membrane (Schleicher & Schuell) for further 
hybridization analysis. High stringency hybridizations were 
carried out at 52°c in the same hybridization solution, with 
a final post-hybridization, high stringency wash at 65°C for 
30 min in 0.1 X SSC-0.1% SDS. High stringency 
hybridizations allowed for 7.6% mismatch.
Alcohol Precipitation of DNA
Alcohol precipitation was frequently used for recovery 
and concentration of DNA or for removal of protein, salt, 
and/or unincorporated nucleotides from DNA samples. Either
ammonium acetate (5.0 M) was added to a final concentration 
of 2-2.5 M or sodium acetate (3.0 M) was added to 0.3 M, and 
then 2.5 volumes of 95% ethanol or 1 volume of isopropanol 
were added. If ethanol was employed, the solution was 
chilled for 10 minutes in an ethanol-dry ice bath; whereas, 
for isopropanol precipitation the solution was placed in an 
ice-water bath for 10 minutes. The DNA precipitate was 
collected by centrifugation at 12,000 x g for 15 minutes at 
room temperature in a microcentrifuge. The DNA pellets were 
rinsed with 70% ethanol and dried under vacuum.
DNA Isolation
Lambda DNA isolation. E. coli strain C600 cells were 
used as host cells for making a recombinant AgtlO phage 
plate lysate for DNA isolation according to the method of 
Verma (1989) with minor modifications. Three hundred 
microliters of competent cells were infected with 50,000 
phage by incubating at 37°C for 30 minutes. The infected 
cells were mixed with 6 ml of top agarose at 48°C and plated 
out on a 150-mm NZY agar plate. The plates were incubated 
at 37°C to obtain confluent lysis, usually requiring 6-8 
hours. Phage was eluted from the top agarose with 10 ml SM 
buffer by shaking for two hours on an orbital shaker at room 
temperature. The lysate was pipetted off, and cleared by 
centrifugation at 1,000 x g and then mixed with an equal 
volume of saturated ammonium sulfate to precipitate the
phage. The suspension was kept on ice for 20 minutes and 
then centrifuged at 25,000 x g for 15 minutes at 4CC. The 
phage pellet was suspended in 0.5 ml of 3 M guanidine 
isothiocyanate containing 2.5% sarkosyl and 10 mM EDTA, pH 
7.5. Protease K was added to a final concentration of 1.0 
pg/pl and the solution was incubated at 52°C for 30 minutes. 
The released phage DNA was alcohol precipitated and 
suspended in 0.5 ml of T^E, buffer. DNA was treated with 
RNase A at a final concentration of 50 pg/pl for 20 minutes 
at 37°C, The DNA was extracted once with one volume of T10E1 
buffer-saturated phenol/chloroform (1:1) and once with 
chloroform. After extraction, the DNA was alcohol 
precipitated and resuspended in the appropriate volume of
T 1E 0.1*
Plasmid DNA minioreu. Recombinant plasmid DNA was 
isolated using a modified alkaline lysis method of Birnboim 
and Doly (1979). Cells from a transformed single colony 
were inoculated into 20 ml LB broth with 50 pg/ml ampicillin 
and grown overnight at 37°C with agitation. Cultures were 
centrifuged for 10 minutes at 1,000 x g at room temperature. 
The cell pellets were resuspended by vortexing before adding
1.5 ml SET buffer, transferred to a 1.5 ml microfuge tube, 
then pelleted by a 20-second spin in a microfuge. The cell 
pellet was vortexed until creamy and resuspended in 250 pi 
SET buffer. To lyse the cells and degrade the RNA 
molecules, 0.5 ml freshly-prepared alkaline lysis solution
was added and the tube was gently inverted several times 
then incubated at 65°C for 30 minutes. Three hundred and 
seventy microliters of 5 M potassium acetate, pH 4.8, was 
added, and the solution was mixed and kept on ice for 20 
minutes. The precipitated material was removed from the 
solution by centrifugation in a microfuge for 15 minutes' at 
room temperature. The plasmid DNA was precipitated by 
adding 300 fil 27% PEG/3.3 M NaCl and incubating at 4°C for 
two hours. The DNA was collected by centrifugation for 15 
minutes, rinsed with l ml 70% ethanol, and resuspended in 
400 fil TE buffer. After loading 8 jxl onto an assay agarose 
gel, 400 (il 5 M NH^AC were added, and the DNA was 
precipitated with isopropanol.
Agarose Gel Electrophoresis of DNA
Agarose gels were prepared in 50 mM TBE buffer with EBr 
(0.5 jug/ml) at final agarose concentrations ranging between 
0.7-1.8%, depending upon the size of the DNA fragments to be 
separated. The agarose was melted by boiling in buffer in a 
microwave oven and allowed to cool to 65°C before being 
poured into an appropriate mold with a well-forming comb.
DNA samples were mixed with 1/5 volume of SOG loading buffer 
prior to loading. Gels were electrophoresed in 50 mM TBE 
buffer containing 0.5 Mg/ml EBr at constant voltage (50 or 
loo volts) until the tracking dye reached the desired 
position. The DNA was visualized by uv-transillumination
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and photographed with Polaroid type 55 positive/negative or 
type 667 high speed positive films.
DMA Restriction Enzvme Digestion
The restriction enzymes used in this study, their 
recognition sequences, and their reaction buffers are listed 
in Appendix XX. The DMA subjected to restriction enzyme 
digestion was diluted into the appropriate enzyme buffer. 
Restriction enzyme was added at 1 unit//xg of DNA. Nuclease- 
free BSA and BME were added to all reactions at 
concentrations of 100 ^g/ml and 6 mM, respectively. The 
samples were incubated at 37°C for 2-16 hours (65°C for 
TaqI).
Electroelution of DNA Fragments
DNA restriction fragments were separated by 
electrophoresis through an appropriate agarose gel. The DNA 
band of interest was located with long-wavelength 
ultraviolet illumination. A slice of agarose gel containing 
the desired DNA fragment was excised with a razor blade and 
placed into elution wells of an electroeluter (International 
Biotechnologies, Inc.). Then, 150 /il of 7.5 M ammonium 
acetate/0.01% xylene cyanol solution was placed in the V- 
shaped channels of the electroeluter, and the DNA was eluted 
from the gel at 50 volts for one hour in 1 X TAE buffer.
The eluted DNA in the ammonium acetate was recovered by 
alcohol precipitation.
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Ligations
The pTZl9U plasmid vector DNA was digested with the 
appropriate restriction enzyme to generate ends compatible 
with those of the DNA fragment to be inserted. The digested 
vector DNA was treated with CIAP to remove the 5'-terminal 
phosphates to prevent self-ligation. The inserts of the 
cDNA clones or their restriction enzyme fragments of 
interest were mixed in about equal molar amounts (0.2 pmole) 
with plasmid vector DNA. The DNA mixture was heated at 65°C 
for 5 minutes and brought up to a final volume of 10 pi in 1 
X ligation buffer containing 1-2 units of T4 DNA ligase.
The reaction was incubated at room temperature for 30 
minutes, and then at 16°c for 16 hours.
Bacterial Transformation
Transformations were carried out using a modified 
procedure of Maniatis et al. (1982). Competent cells were 
prepared by growing E. coli (strain JM101 or MV1304) in LB 
broth at 37°C to an OD60(J of 0.4-0.6. The cells were chilled 
on ice, collected by centrifugation at 5000 x g for 10 
minutes, resuspended in 1/4 the culture volume of ice-cold, 
sterile 0.1 M MgCl2, and allowed to stand on ice for 20 
minutes. After a second centrifugation at 5000 x g, the 
cells were resuspended in 1/50 the original culture volume 
of 50 mM CaCl2, and kept on ice for one hour.
Transformations were performed by adding 1-5 pi of ligation 
mix to 100 pi of competent cells in a sterile, 13-ml glass
test tube and incubating on ice for a minimum of 30 minutes. 
The transformation mixtures were heat-shocked at 42°C for
2.5 minutes and cooled to room temperature before adding 0.5 
ml LB broth. The cells were incubated at 37°c for 30 
minutes with shaking; another 0.5 ml LB broth containing 100 
/ig/ml ampicillin was added, and the incubation was continued 
for another 30 minutes. The cells were plated onto LB agar 
plates containing 50 jil/ml ampicillin. Only transformed 
cells which obtained ampicillin resistance were able to grow 
on these plates.
DMA Sequencing
DNA nucleotide sequences were compiled and analyzed 
using the Hitachi DNASIS computer software (version 5.02). 
Amino acid sequences were deduced from their cDNA and 
analyzed using the Hitachi PROSXS software (version 5.02).
Denaturation of double-stranded DMA. Double stranded 
recombinant pTZ19U plasmid DNA (2-3 (ig), prepared by the 
standard alkaline minipreparation procedure, was denatured 
in 0.2 N NaOH for 5 minutes at room temperature. The sample 
•was neutralized by adding 0.4 volume of 5 H ammonium acetate 
(pH 7.0), and then the DMA was precipitated with 4 volumes 
of 95% ethanol at -45°c for 10 minutes. After washing the 
pelleted DNA with 70% ethanol and vacuum drying, the DNA was 
redissolved in 7 |tl of dH20.
DNA dideoxvnuclaotide sequencing reactions. All 
nucleotide sequencing was performed by the dideoxynucleotide 
sequencing method (Sanger et al., 1977) using the Sequenase 
DNA sequencing kit according to the manufacture's protocols. 
The denatured DNA (2-3 /ig) was primed with either M13 
universal or reverse primer in a total volume of 10 til in 
1 X Sequenase buffer. The molar ratio of primer to template 
was 1:1 (0.5 pmol). The reaction was completed by 
incubating the mixture at 65°C for 2 minutes, placing in a 
beaker of 65°C water, and allowing to cool slowly to room
temperature over a period of 30 minutes. To the annealed
DNA, 1 jtl of 0.1 H DTT, 2 til of labeling mix (1.5 fiH of
dGTP, dCTP and dTTP), 0.5 /il of [35S)dATP (10 ftC) , and 2 fil
of 1:8 diluted Sequenase were added. The labeling reaction 
was carried out at room temperature for 5 minutes before 
aliquoting 3.5 jliI of the mix into a set of 4 tubes which 
contained 2.5 fil of the appropriate termination mix 
(containing 80 /iM deoxynucleotides and 8 of the 
appropriate di-deoxynucleotide). The termination reactions 
were incubated at 37°C for 5 minutes and stopped by adding 4 
fil of stop solution (95% form amide, 20 mM EDTA, 0.05% 
bromophenol blue and 0.05% xylene cyanol FF). The samples 
were heated at 80°C for 2 minutes and chilled on ice just 
before loading onto the assay gels.
DNA sequencing ael electrophoresis. An IBI model STS 
45 apparatus with a 64 well comb was used to perform the DNA
sequencing gel electrophoresis. The sequencing gels 
contained 6-8% polyacrylamide (acrylamide/bis : 19/1) and 
8.3 M urea in 50 mM TBE buffer. The gel solution was 
filtered and vacuum degassed. Just before pouring, ammonium 
persulfate and TEMED were added to 0.07% (w/v) and 0.03% 
(v/v), respectively. The gel solution was poured between 
two glass plates with 0.4-0.8 mm wedge spacers and allowed 
to polymerize for at least one hour. The gel was pre- 
electrophoresed at 1600 volts for a minimum of 30 minutes in 
50 mM TBE buffer. Aliquots of 3.5-6 jxl of each sequencing 
mix were loaded into wells, and electrophoresis was 
continued until the tracking dye had reached the desired 
positions. After the gel was soaked in 10% acetic acid-12% 
methanol for 45 minutes to precipitate the DNA and to remove 
the urea, it was then dried onto Whatman 3 MM paper at 80°C 
and subjected to autoradiography.
Hybridization of Filter Bbnded DNA
Radioisotopic labeling of DNA probes. Radioactive DNA 
fragments were prepared for use as hybridization probes 
either by random primer labeling (Feinberg and Vogelstein, 
1984) or nick translation (Maniatis et al., 1982). For both 
methods, approximately 0.1-0.5 fig of DNA and either [a- 
3aP]dATP or [a-32P]dCTP, as radioactive nucleotide, were used 
in each labeling reaction. For random primer labeling, the 
DNA was denatured by heating for 10 minutes at 90°C and
subsequent cooling on ice. A mixture of random sequence 
hexadeoxynucleotides, all deoxynucleotides except the one 
which was to be used in radioactive form, reaction buffer 
(Promega), and 10 pci radioactive nucleotide were added.
The reaction was started by adding 2 units of Klenow enzyme, 
and, after incubating at 37°C for 30 minutes, was stopped by 
adding 2 pi of 0.2 M EDTA and heating to 65°C for 10 
minutes. Nick translation was done by diluting DNA into a 
reaction mix containing nick translation buffer (Bethesda 
Research Laboratories), deoxynucleotides, and about 10 pCi 
radioactive nucleotide. Labeling was started by the 
addition of 2 units of DNA polymerase I and 0.2 ng of DNase 
I; the reaction was incubated at 15°C for 60 minutes and 
terminated by adding 0.5 M EDTA to 30 mM. DNA labeled by 
either procedure was precipitated twice with ethanol and 
resuspended in an appropriated volume of hybridization 
buffer.
The synthetic oligonucleotide probe was radiolabeled at 
its 5'-terminus 37°C for 30 minutes with 166 pci [y -3zP]ATP.
A total volume of 15 pi of 1 X kinasing buffer containing 
100 ng oligonucleotide and 8 units of T4 polynucleotide 
kinase. Then, the enzyme was inactivated at 65°C for 5 
minutes. The labeled oligonucleotide was ethanol 
precipitated.
Slot-blotting of nucleic acids. Slot-blotting was 
performed by using a Bio-Rad 48 slot filtration apparatus.
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A DNA sample for slot-blotting was denatured in 0.2 N NaOH 
at 65°C for 30 minutes and then neutralized with 3.5 volume 
of 1 M Tris-HCl/2 M NaCl (pH 7.0). Hybridization membranes 
(either nitrocellulose or Nytran) were wetted sequentially 
in dHz0, then 12 X SSC. Aliquots of 20-200 fil of the DNA 
solution were slotted onto the membrane by vacuum 
filtration. RNA samples were prepared in 6 X SSC/7% 
formaldehyde and heated at 65°C for 15 minutes before 
applying to a nitrocellulose membrane. The NaOH-treated 
control RNA samples were made in 0.2 N NaOH, heated at 65°C 
for 30 minutes, and neutralized by adding 2 volumes of 1 M 
Tris-HCl (pH 6.0). The membranes were baked at 80°C for 30 
minutes.
Southern and northern blotting. Samples of mouse 
genomic DNA were digested with several restriction 
endonucleases. After agarose gel electrophoresis to 
separate the DNA fragments, the gel was stained in 50 mM TBE 
buffer containing 0.5 jig/ml EBr for 15 minutes and 
photographed using transmitted UV light. The gel was then 
soaked in 0.25 N HCl for 20 minutes, rinsed with dHzO, and 
soaked in 0.4 N NaOH twice for 15 minutes each to denature 
and cleave the DNA backbone at the acid-depurinated sites. 
The gel was neutralized by soaking in 1 M Tris-HCl (pH 7.4) 
for 20 minutes. After a brief rinse with 10 X 5SPE, DNA in 
the gel was transferred onto a nitrocellulose or Nytran 
membrane with 10 X SSPE employing either a standard
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capillary blotting apparatus (Southern, 1975) or using a 
VacuBlot apparatus (American Bionetics) according to 
manufacture's directions.
Northern blotting was performed according to Maniatis 
et al. (1982). Poly(A) + RNA samples were precipitated with 
ethanol. After resuspending in dH2Of the RNA samples were 
denatured for 15 minutes at 65°C in formaldehyde (2.2 
M)/formamide (50%), loaded onto and electrophoresed in a 2.2 
M formaldehyde-1.5% agarose gel. The gel was soaked 
sequentially in dHao and 20 X ssc and the RNA was 
transferred to a nitrocellulose membrane by capillary 
blotting.
Stripping probe from filters. Previously hybridized 
probes were stripped off Nytran membranes by boiling the 
filter for 20 minutes in 0.01 X SSPE/0.5% SDS. Probes bound 
to nitrocellulose filters were stripped by two 20-minute 
washes at 65°c in 50% formamide, 2 X SSC, and 0.5% non-fat 
skin milk. After stripping, the filters were rinsed in 2 X 
SSPE or SSC and exposed to X-ray film to check for complete 
removal of the probe.
Autoradioqraphv. Membranes and gels containing 3ZP- 
labeled DNA were sealed in plastic bags or cover with 
plastic wrap, respectively, and directly exposed to Kodak 
XAR-5 film with two Du Pont cronex Lightning Plus 
intensifying screens at -85°c for several hours to three
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weeks. Gels with 35S-labeled DNA were dried onto Whatman 3 
KM paper before exposure to XAR-5 film at room temperature. 
All films were developed up to 7 minutes in Kodak GBX 
developer, fixed for 10 minutes in Kodak GBX Fixer, and then 
rinsed in running water for 15 minutes before air drying.
CHAPTER 3 
Results
Morphological changes of Mouse Hast Cells Induced with
FCM or Sodium Butvrate 
ABFTL-6 cells contain a relatively low amount of small 
cytoplasmic granules. When the cells were cultured in the 
media containing 50% FCM for 10 days or in the presence of 1 
mM sodium butyrate for 4 days, the majority of the cells 
increased in size as well as in cytoplasmic granulation.
The results shown in Figure 5 are representative of mast 
cell populations in each category of a typical experiment. 
The photographs were taken at the same magnification and at 
random field positions of cells stained with either 
toluidine blue or alcian blue. By comparison to the 
untreated mast cells {Panel A), the mast cells induced with 
either FCM (Panel C) or butyrate {Panel B) significantly 
increased their average cell volumes. This increase in cell 
size was evident after four days for FCM, or two days for 
sodium butyrate treatment, respectively. Also, the granules 
were larger and were stained more intensely with the 
metachromatic dye toluidine blue upon induction.
Effects of FCM and Sodium Butvrate Culture on 
Mast Cell Trvotase Activity and Antigen Levels 
Tryptic activity was identified in high salt extracts of the 
mast cells by enzymatic assays using synthetic substrates.
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Figure 5. 
Morphological 
changes of 
ABFTL-6 cells 
induced by 3T3 
FCM and by 
sodium butyrate.
(A) Uninduced 
control cells 
stained with 
toluidine blue.
(B) Cells were 
grown for 4 days 
in the media 
containing 1 mM 
sodium butyrate 
and stained with 
alcian blue,
(C) Cells were 
grown for 10 
days in the 
media containing 
50% FCM and 
stained with 
toluidine blue. 
Photographs were 
taken from 
random fields of 
stained slides 
with Kodak
Ektachrome 50 
slide film. 
(Magnification 
X576).
In order to clarify the tryptic activity identified in these 
mast cells, several serine proteinase inhibitors were tested 
for their effect on the observed tryptic activity. A unique 
biochemical property of mast cell tryptase, which 
distinguishes it from other serine proteases (i.e. 
pancreatic trypsin), is its resistance to trypsin inhibitors 
such as a-1 protease inhibitor (a-l-PI) and lima bean 
trypsin inhibitor (LBTI). The inhibition profile obtained 
is presented in Figure 6.
The tryptic activity was almost totally abolished by 
the strong serine protease inhibitors PMSF and DFP, and 
significantly inhibited by antipain and benzamidine. An 
irreversible chymotrypsin inhibitor that alkylates the 
active site histidine TPCK, showed partial inhibition (40%). 
A trypsin inhibitor with the same mechanism as TPCK, TLCK, 
caused 77% inhibition. It seems likely that some of the 
tryptic activity in the cell extract may be due to 
chymotryptic enzyme. However, TPCK also partially inhibited 
purified mast cell tryptases from human lung (70% activity), 
and dog mastocytoma (80% activity) (Caughey et al., 1987; 
Smith et al., 1984). TLCK had a similar effect on the 
tryptase isolated from a human mast cell line (24% activity, 
Butterfield et al., 1990). Like other tryptases, this 
activity was not affected by either a-l-PI or LBTI. It was 
less susceptible to inhibition by benzamidine 
(63% inhibition) than tryptases from human lung
PMSF
20 40 60 80 100
%  Activity
Figure 6. In vitro inhibition profile of mouse mast cell 
tryptase. A single lysate from FCM induced ABFTL-6 cells 
was used for all inhibition studies. The residual tryptic 
activity presented was calculated relative to the control, 
which contained no inhibitor (100% activity).
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(96.5% inhibition) and dog (95% inhibition). However, the 
tryptase isolated from human mast cells was more resistant 
to benzamidine inhibition (20% activity). The inhibition 
profile in Figure 6 is similar to those of purified dog mast 
cell tryptase and human tryptases, indicating that the 
tryptase activity of the ABFTL-6 cells is due primarily to 
similar tryptase(s).
Furthermore, a tryptase antigen was identified in the 
ABFTL-6 cell extracts, which reacted with antibodies against 
human mast cell tryptase. Both immuno-dot and Western blots 
analyses were positive and suggested structural similarities 
between mouse and human tryptases (see Figure 8 and 9 
below). The evidences provided by the inhibition study and 
the immuno-blotting analyses support the conclusion that the 
ABFTL-6 tryptic activity was due to the mast cell tryptase.
Upon treatment with FCM or sodium butyrate, there was 
an increase in total cellular protein (Figure 7). Tryptase 
activity and antigen levels in the cell extracts also 
increased strikingly. The mean of tryptic activity of 
induced ABFTL-6 mast cells was 1.66 units/106 cells for the 
FCM culture (n=5) and 0.82 units/106 cells for sodium 
butyrate treatment (n=7) (Table 2). These levels were about 
13- and 6-fold higher than the control level (0.13 units/106 
cells, n=7) upon induction with FCM and sodium butyrate, 
respectively.
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Figure 7. The effects of 3T3 FCM and sodium butyrate 
treatment on tryptic activity and total cellular protein of 
ABFTL-6 cells. Data are presented as mean + SD of three 
separate experiments, each carried out in duplicate.
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Figure 8. Immuno-dot blot quantification of total tryptase 
antigen in the induced and the uninduced ABFTL-6 mast cells. 
Cell lysates were diluted and the amount of lysate 
equivalent to a fixed number of cells (as indicated in the 
right margin of the figure) was applied to each row of the 
blot. Human mast cell tryptase was used as standard and was 
shown to the left of the figure. A rabbit IgG against human 
tryptase was used as the primary antibody. The tryptase 
antigen was detected by using goat anti-rabbit IgG-alkaline 
phosphatase conjugate as a secondary antibody. Panel A, 
human mast cell tryptase standard. Panel B, 10-day FCM 
culture of ABFTL-6 mast cells. Column B1 and B2 represent 
different preparations of induced cells. Panel C, uninduced 
ABFTL-6 cells.
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Table 2. The Effect of FCM and Sodium Butyrate on Tryptase 
Expression in ABFTL-6 Mouse Mast Cells
Treatment1
FCM Butyrate Control
Total Protein 
(mg)
0.33 ± 0.20 
(n=5)
0.27 ± 0.13 
(n=6)
0.09 ± 0.02 
(n=5)
t
Tryptic
Activity (unit)
1.66 ± 0.39 
(n=5)
0.82 ± 0.51 
(n=7)
0.13 ± 0.08 
(n=7)
Total Tryptase 
Antigen2 (Mg)
125 75 2.3
Tryptase 
Antigen to 
Total Protein
38% 28% 2.7%
1 The data were expressed as the mean ± standard deviation 
for 106 cells. N is the number of individual cell 
cultures measured.
2 Total tryptase antigen was calculated from the data in the
dot-blot immunoassay based on a standard of human
tryptase. This determination was performed once.
Immuno-dot blots were used to quantify the tryptase 
protein in cell extracts and to monitor the tryptase antigen 
levels upon induction (Figure 8). A data summary table of 
tryptase induction of FCM and butyrate is shown in Table 2. 
The value for tryptase concentration in cell extracts is a 
relative value since purified human tryptase was used as the 
standard under the assumption that mouse tryptase is 100% 
reactive to human tryptase antibody. Statistical analysis 
(pared t test) revealed that the increases of both total 
cellular protein and tryptic activity induced by FCM or 
sodium butyrate are significant (p < 0.1). Figure 9 shows a 
Western blot analysis with an antibody against human 
tryptase. significant increases in tryptase antigens were 
observed in both FCM and sodium butyrate treated cells; the 
highest increase was found in the cells induced with FCM.
To check whether the increased tryptic activity was due to 
the frequent media changes, the following control was 
performed. ABFTL-6 cells were grown in unsupplemented media 
which was replaced by fresh media when the media was changed 
on the induced cells. Cells were seeded at the same density 
and maintained for the same length of time as the induced 
cells. There was no statistical difference between the 
tryptic activity of these control cells and the starting 
cells. As seen in Figures 9 and 11, there was no 
significant visual difference in the tryptase antigen level 
between these cell populations and the starting cells.
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Figure 9. Western blot analysis for tryptase antigen in 
induced and uninduced ABFTL-6 mast cells. The proteins in a 
cell lysate equivalent to 0.7 x 106 cells were precipitated 
by 20% TCA, resuspended, and separated by electrophoresis on 
a 10% SDS-polyacrylamide gel. The separated proteins were 
electroblotted to a nitrocellulose membrane which was then 
probed with an affinity-purified antibody against human 
tryptase. (A) Molecular weight standards; (B) starting 
ABFTL-6 cells; (CJ control ABFTL-6 cells for sodium butyrate 
treatment; (D) sodium butyrate treated ABFTL-6 cells; (E) 
control ABFTL-6 cells for FCM treatment; (F) FCM induced 
ABFTL-6 cells; (G) human mast cell tryptase.
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Figure 10. Western blot analysis of sodium butyrate- 
induced tryptase antigen in ABFTL-6 cell lysates. Fifty 
micrograms of lysate protein were precipitated by 20% TCA 
and separated by electrophoresis on a 7.5% SDS- 
polyacrylamide gel and blotted to a nitrocellulose membrane. 
Rabbit anti-human tryptase antibody and goat anti-rabbit IgG 
antibody conjugated to alkaline phosphatase were used as 
primary and secondary antibodies, respectively. (A) Lysate 
of ABFTL-6 control cells; (B) lysate of ABFTL-6 cells grown 
in 2 raM sodium butyrate for four days; (C) lysate of ABFTL-6 
cells grown in 1 mM sodium butyrate for four days; (D) human 
tryptase standard (l ug).
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The effect of different concentrations of sodium 
butyrate on the induction of tryptase was examined. As 
shown in Figure 10, 1 mM butyrate-supplemented media induced 
more tryptase expression than 2 mM butyrate-supplemented 
media. A notable feature of this blot is that the band in 
lane C seems to contain two closely spaced bands, indicating 
tryptase heterogeneity.
Both FCM and Sodium Butyrate Increased Total 
DFP-Bindino Proteins 
DFP is a strong serine protease inhibitor which is able 
to irreversibly bind to the active site serine residue of 
all serine proteases. Figure 11 shows an autoradiograph of 
[3H] DFP-labeled proteins from induced and uninduced ABFTL-6 
mouse mast cells. The cell extracts were incubated with an 
excess of TPCK, a chymotrypsin inhibitor, before reaction 
with [3H] DFP to abolish the possible binding of the [3H]
DFP to chymase. Therefore, the bands observed in this 
autoradiogram are most likely due to tryptases, but could 
represent other serine proteases. As shown in this figure, 
the intensity of the bands corresponding to a Mr of 35 KDa 
in sodium butyrate or FCM induced mast cells increased 
significantly from those found in uninduced mast cells. The 
degree of the increases of "DFP-binding protein” is 
comparable to the increases of tryptase antigen observed by 
Western blot analysis (see Figure 9). Some high molecular 
weight bands were seen in some extract preparations.
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Figure IX. Autoradiography of gel fractionated [3H] DFP- 
labeled proteins in ABFTL-6 cell lysates. A lysate 
equivalent to 0.7 x 106 cells of each cell sample was 
incubated with excess [3H] DFP, as described in Materials 
and Methods, and separated on a 10% SDS-polyacrylamide gel. 
(A) The positions of the prestained standards were marked on 
the dried gel with radioactive ink. (B) Human lung mast 
cell tryptase (1 ug). (C) ABFTL-6 cell grown in 1 mM sodium
butyrate. (D) ABFTL-6 control cells for sodium butyrate 
treatment. (E) 3T3 FCM induced ABFTL-6 cells. (F) ABFTL-6 
control cells for 3T3 FCM treatment. (G) Starting ABFTL-6 
cells.
• w’* ' .
Possibly, they are enzyme aggregates or non-specific DFP- 
binding proteins. Differences in the molecular weight of 
mouse tryptase observed between the Western blot and the 
autoradiography of DFP-binding study were noticed.
Molecular Cloning of House Mast Cell Trvptases 
The yield of total RNA isolation from ABFTL-6 cells was 
2.8 /jig/106 cells. The poly (A)* RNA was isolated from the 
total RNA at 4.2% recovery rate. A RNA slot blot 
hybridization analysis was performed using RNA from ABFTL-6 
cells to determine whether RNA homologous to the dog 
tryptase cDNA exists in these mouse mast cells. As shown in 
Figure 12, RNA slot-blot hybridizations revealed that the 
900 bp dog tryptase cDNA strongly hybridized under standard 
stringency conditions to the poly(A)* RNA isolated from 
ABFTL-6 cells, indicative of a high level of tryptase 
expression in these cells. The hybridization in the 
poly(A)+ RNA fraction was due to RNA since there was no 
apparent DNA contamination in that fraction, as evidenced by 
the lack of hybridization in the corresponding NaOH-treated 
RNA sample. The NaOH treatment, which completely degrades 
RNA, but not DNA, demonstrated that the positive result was 
due to hybridization to RNA and not to contaminating DNA.
The strongest hybridization was found in the low salt wash 
fraction which contains mostly short, poly(A)+-tailed RNA, 
unable to bind tightly to the oligo(dT) column, suggesting 
that most tryptase messengers only bear short poly(A)*
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Figure 12. Mouse mast cell RNA slot-blot hybridization 
analysis for tryptase-encoding sequences. Poly(A)+ RNA of 
mouse mast cells was isolated by two cycles of oligo (dT) 
cellulose chromatography. The poly (A)+, low salt wash and 
poly(A)' RNA fractions were collected and slot-blotted onto 
a nitrocellulose membrane. Hybridization was carried out at 
standard conditions, with dog mast cell tryptase cDNA as 
probe. (A) Formaldehyde-denatured RNA; (B) NaOH-treated 
RNA; (C) NaOH-treated mouse genomic DNA as control. Lane 1 
and 2 contain 1 and 3 /ig RNA, respectively. Row a and b 
contain 0.4 and 2 /ig of DNA, respectively.
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tails. Only very faint bands were seen in the denatured 
mouse genomic DNA, suggesting the number of tryptase genes 
may be small.
A cDNA library was constructed from the poly(A)+ RNA 
isolated from mouse mast cells. Initial screening of the 
mouse mast cell cDNA library with the dog tryptase clone 
yielded several hundred (0.5% frequency) hybridization- 
positive plaques. Twenty positive clones were arbitrarily 
selected for further studies and were plaque purified prior 
to isolating their DNA. Digestion of the recombinant phage 
DNAs with EcoRI released inserts that ranged in size from 
950 to 1200 bp. The isolated recombinant phage DNAs were 
slot-blotted onto a nitrocellulose membrane for rescreening 
with the dog tryptase cDNA probe under defined conditions. 
These included highly stringent hybridization conditions 
which allowed for approximately 7.6% mismatch. The blot was 
made in duplicate. One was hybridized to dog tryptase DNA; 
the other to lambda DNA to determine the relative amount of 
recombinant vector DNA loaded in each slot. Also included 
were samples of the cDNAs for dog tryptase and RMCF II.
Figure 13 shows the autoradiograms of the DNA slot-blot 
hybridization patterns under highly stringent conditions. 
Although all the clones hybridized to dog tryptase cDNA at 
the standard conditions (data not shown), some of them 
hybridized poorly at highly stringent condition. For 
example, clone #4 6 and #24 had little hybridization
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Figure 13. Hybridization analysis of DNA from tryptase- 
positive clones by slot blotting. DNA of tryptase-positive 
lambda clones was isolated, denatured and slot-blotted onto 
a nitrocellulose membrane at two different concentrations,
20 ng and 200 ng (based on ethidium bromide staining 
intensity in agarose gels). A and B are duplicate blots and 
were hybridized at highly stringent conditions requiring 
92.4% sequence complementary. DNA samples are numbered at 
their left, Trp - dog tryptase cDNA, Chy - RMCP II cDNA.
(A) Blot hybridized with lambda DNA probe; (B) Blot 
hybridized with dog tryptase cDNA probe.
67
(Panel B), although they contained equivalent amounts of DNA 
as judged from their hybridization to lambda DNA (Panel A). 
The figure also shows that there was no cross-hybridization 
between dog tryptase and RMCP II (chymase) cDNAs, or between 
dog tryptase and lambda DNA.
Five clones (ATI, AT4, AT26, AT55 and AT85) showed 
strong hybridization under these highly stringent 
conditions, clone AT86 hybridized less intensely, but 
contained the longest insert. The inserts in these six 
clones were subcloned into pTZ19U plasmid and their 
nucleotide sequences were determined. The subcloning and 
sequencing strategy are presented in Figure 14. The 
sequences obtained fell into two groups each of which coded 
for a distinct tryptase. The first group consisted of 
clones pAT4, pATl and pAT86, designated as mouse tryptase I; 
the second group contained pAT26, pAT55 and pAT85, and was 
designated as mouse tryptase II. clones pAT4 and pAT26 were 
chosen as representatives of mouse tryptase I and tryptase 
II, respectively. These cDNAs were cleaved into 
subfragments by PstI and Sau3A for subcloning in order to 
obtain sequence data from both strands.
The cDNA's composite nucleotide sequence for mouse 
tryptase I and its derived amino acid sequence are presented 
in Figure 15. Tryptase I cDNA is 1086 bp long, contains an 
open reading frame of 822 bp, and a 3'-noncoding region of 
264 bp. The putative sequence for the polyadenylation
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Mouse Tryptase I Mouse Tryptase II.
Q CO Q  P)
ir nj 1/5 fa nl tSnj
q  17 Off _ (A)n q  °<Q — (A)n
200bp 200bp
p*T4 u — l-----  P*T26 II
P ^ T 8 6  i p X T 5 5  n  1—
pAT1 m  1  pAT85 EE
Figure 14. strategy used to subclone and sequence the cDNAs 
for the mouse mast cell tryptases. The rectangles represent 
the open reading frames of the cDNA clones. The hatched and 
open areas show the regions encoding the putative 
signal/activation peptide and the active tryptase, 
respectively. The intron found in clone p>,T86 is denoted as 
a dotted box below the open reading frame. The thick lines 
designate the 3'-noncoding region. The thin lines with 
arrows indicate the length and direction of nucleotide 
sequences obtained by dideoxnucleotide sequencing of the 
cDNAs and their subclones. All sequence data was verified 
by sequencing both strands of the cDNA.
Figure 15. The composite cDNA's nucleotide and derived 
amino acid sequence of mouse tryptase X. The numbers on the 
right and left sides of the sequence indicate the nucleotide 
positions. The amino acid sequence deduced from the cDNA is 
shown in single-letter code above the first nucleotide of 
each codon, and are numbered above every tenth residue.
Amino acid residues -29 to -1 represent the 
signal/activation peptide. The amino acid residues which 
comprise the catalytic triad (Hisw , Asp91 and Ser194) are 
marked with stars. The solid square labels the substrate- 
binding pocket Asp188 residue. The potential N-linked 
glycosylation site, Asn102, is marked with a dot. The solid 
arrow indicates the location of the intron found in clone 
plT86. The putative polyadenylation signal sequence is 
underlined.
M o u se  M a s t  C e l l  T r y p t a s o  I
1
6 1
121
101
241
3 0 1 .
3 6 1
4 2 1
4 0 1
5 4 1
6 0 1
6 6 1
7 2 1
7 0 1
0 4 1
9 0 1
9 6 1
1021
1 0 8 1
-20 -10 
L K R L L L L W A L S L L A S L V Y S A  
CTGAAGCGGCTGCTGCTGCTGTGGGCACTGTCCCTCCTGGCTAGTCTGGTGTACTCAGCC 60
-1 +1 10
P R P A N Q R V G I V G G H E A S E S K  
C CTCG CC CAG C CAATCAG CGAGTGG G CATCGTGG G A GGACATGAGGCTTCTGAGAGTAAG 1 2 0
2 0  3 0
W P W Q V S L R F K L N Y W I J I F C G G  
TGGCCCTGGCAGGTGAGCCTGAGATTTAAATTAAACTACTGGATACATTTCTGCGGAGGC 1 0 0
4 0  ★  • 5 0
S L X H P Q W V L T A A H C V G P I I X K  
TCTCTCATCCACCCA CAGTCG GTG CT CACTGCGG CA C A CTGTGTG G C A CCW CACATCAAA 2 4 0
6 0  ' 7 0
S P Q L F R V Q L R E Q Y L Y Y G D Q L  
AGCCCACAGCTCTTCCGGGTGCAGCTTCGTGAGCAGTATCTATACTATGGGGACCAGCTC 3 0 0
00 90 -A-
L S L N R X V V H P I 1 Y Y T A E G G A D  
CTCTCTTTGAACCGGATCGTGGTGCACCCCCACTATTACACGGCCGAGGGTGGGGCAGAC 3 6 0
100 • 110 
V A L L E L E G P V N V S T H I H P I S  
GTTGCCCTGCTGGAGCTTGACGGTCCTGTGAATGTCTCCACCCATATCCACCCCATATCC 4 2 0
1 2 0  1 3 0
L P P A S E T F P P G T S C W V T G W G  
CTGCCCCCTGCCTCCGAGACCTTCCCCCCTCGGACATCGTGCTGGGTGACAGGCTGGGGC 4 0 0
1 4 0  1 5 0
D 1 D N D E P L P P P Y P I . K Q V K V P  
GACATTGATAATGACGAGCCTCTCCCACCTCCTTATCCTCTGAAGCAAGTGAAGGTTCCC 5 4 0
1 6 0  1 7 0
X V E N S X t C D R K Y l l T G L Y T G D D  
ATTGTGGAAAACAGCCTGTGTGACCGGAAGTACCACACTGGCCTCTACACGGGAGATGAT goo
1 0 0  H 1 9 0
F P I V H D G M L C A G H T R R D S C Q  
TTTCCCATTGTCCATGATGGCATGCTGTGTGCTGGAAATACCAGGAGAGACTCCTGCCAG G60
At 200 210
G D S G G P L V C K V K G T W L Q A G V  
GGCGATTCAGGGGGGCCACTGGTCTGCAAACTGAAGGGTACCTGGCTGCAGGCAGGAGTG 7 2 0
2 2 0  2 3 0
V 5 W G E G C A Q P N K P G I Y T R V T  
GTCAG CTG GGGTGAGGC CTG CG CACAG C CCAACAAG C CTG G CATCTACACCCGGGTGACA 7 0 0
2 4 0
Y Y L D W I I t R Y V P E I I S  End
TACTACTTAG A CTG C AT CCACCG CTATGTCCCTG AG C ATTC CTG AG ACCTATCC A GGGTC 0 4 0
AGGCAAGAACCAGGG CCGTCGTGT CTTTAA CTCACTG CTTCCTG GTCAGGTGGAACC CTT 9 0 0  
GCCTTCCTTGTCCTCTGTCTCCCCTGTCTACTAAATGTCCCTCTGAGGCCCCCACCCCCC 9 6 0  
AG TTCCGTCTTGAGTC C CTAG CCATT CG GTTC CCTCTTG C CT CC CACCACATAATAGTTG 1 0 2  0 
CATTGTGTGGCTCCCTCTCTTCTGTCGCTCATTAAAGTACTTGAAAACAGCTATTGGAAA 1 0 0  0 
AAAAAA
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signal, ATTAAA, is present 21 bases upstream from the 
poly(A) tail. The open reading frame encoded a peptide of 
274 amino acids and terminated at a TGA stop codon.
The nucleotide and derived amino acid sequences of 
mouse mast cell tryptase II is given in Figure 16. The 
compiled nucleotide sequence of tryptase II is 986 bp long, 
consisting of an open reading frame of 801 bp and a 185 bp 
3'-untranslated region. The presumed polyadenylation 
signal, AATAAA, begins 18 nucleotides 5* to the poly(A) 
tall. The two mouse tryptases share 75% and 70% sequence 
identities at their nucleotide and amino acid levels, 
respectively. The base composition of the mouse tryptase 
cDNAs are high in G and C. The percentage of overall G + C 
content for both mouse tryptase cDNAs is 56%, compared to 
41% for average mouse genomic DNA (Arrighi 6t al., 1970). 
Both ipouse tryptases I and II contain a short poly (A) * tail 
of only 9 bases. This is consistent with the results of RNA 
slot-blot hybridization showing high levels of tryptase RNA 
in the low salt fraction, which contained short poly(A)* 
tails (see Figure 12).
The apparent functional domains of mouse mast cell 
tryptase I and II, like dog tryptase, consist of 245 amino 
acid residues. Each enzyme exhibits all the features 
characteristic of a serine protease. The functional domains 
start with the typical Ile-Val-Gly-Gly sequence and have the 
active site charge-relay residues His44, Asp91, and Ser194
Figure 16. Mouse mast cell tryptase IX cDNA's nucleotide 
and its derived amino acid sequences. The amino acid 
sequence deduced from the cDNA is shown in single-letter 
code above the first nucleotide of each codon, and numbered 
above every tenth residue. Amino acid residues -22 to -1 
represent the signal/activation peptide. The labeling and 
notations are the same as in Figure 14. Notice that the 
putative glycosylation site at Asn21 does not exist in mouse 
tryptase I.
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H o u s e  H a s t  C o l l  T r y p t a s e  I I
-20 -10 
L T & P L t i S S L V H A A P G P A M T R  
1 CTCACGCTGCCCCTCCTGTCCAGCCTGGTGCATGCAGCCCCCGGTCCAGCTATGACACGA
-1 +1 10
E G  I V G G Q E A 1 I G N K W P W Q V S L  
G1 GAAGGCATTGTGGGGGGACAGGAGGCACATGGGAACAAGTGGCCCTGGCAGGTGAGCCTG
2 0  »  3 0
R A N D T Y W M H F C G G S L I H P Q W  
1 2 1  CGTGCCAATGACACCTACTGGATGCATTTCTGCGGTGGCTCCCTCATCCACCCACAGTGG
4 0  Ar 5 0
V L T A A H C V G P D V A D P N K V R V  
1 0 1  GTGCTCACTGCGGCACACTGTGTGGGACCGGATGTTGCTGACCCCAACAAGGTCAGAGTA
6 0  7 0
Q L R K Q Y L Y Y H D I I L M T V S Q I I  
2 4 1  CAGCTCCGTAAGCAGTACCTCTATTACCATGACCACCTGATGACTGTGAGCCAGATCATC
00 9 0  Ar
T H P D F Y I V Q D G A D I A L L K L T  
3 0 1  ACACACCCCGACTTCTACATCGTCCAGGATGGGGCAGACATTGCCCTGCTGAAACTCACA
100 O 110
N P V H I S D Y V H P V P L P P A S E T  
3 6 1  AACCCTCTGAACATTTCTGACTATGTCCACCCTGTCCCCCTACCTCCTGCCTCAGAGACC
1 2 0  1 3 0
F P S G T L C W V T G W G N I D N G V H  
4 2 1  TTCCCCTCAGGAACGTTGTGCTGGGTGACAGGCTGGGGTAACATCGACAATGGTGTAAAC
1 4 0  1 5 0
L P P P F P L K E V Q V P I I E N H L C  
4 0 1  CTGCCGCCACCATTTCCTTTGAAGGAGGTGCAAGTTCCCATTATAGAAAACCACCTTTGT
1 6 0  1 7 0
D L K Y H K G L I T G D N V H I V R D D  
5 4 1  GACTTGAAGTATCACAAAGGTCTCATCACAGGTGACAATGTCCACATTGTCCGAGATGAC
100 ri 1 9 0  Ar
H L C A G H E G I I D S C Q G D S G G P L  
6 0 1  ATG CTGTGTGCTGGGAATGAAGGACATGACTCCTGCCAGGGCGACTCCGGAGGACCTCTG
200 210
V C K V E D T W L Q A G V V S W G E G C  
6 6 1  GTCTGCAAGGTAGAAGACACCTGGCTGCAGGCACGCGTGGTCAGCTGGGGTGAGGGCTGT
2 2 0  2 3 0
A Q P H R P G I Y T R V T Y Y L D W I H  
7 2 1  GCACAGCCCAACAGGCCTGGCATCTACACCCGGGTCACCTATTACTTGGACTGGATCCAC
2 4 0
H Y V P  K D F End  
7 0 1  CACTACGTCCCCAAGGACTTCTGAGTCACATCCAGGATGACCTCCGTTCCTCCCAGCATG
60
120
1 8 0
2 4 0
3 0 0
3 6 0
4 2 0
4 0 0
5 4 0
GOO
6 6 0
7 2 0
7 8 0
8 4 0
0 4 1  CTGCTTCCTGCCCGCGTGGCATCCCTCCCTTCCTCTCCTGCTCCCCATCCTGAGTCCCAA 9 0 0  
9 0 1  TTCTTCTGCCTTCCACTCAAGTAGCTACACTGAGCAGGCGCCGCTCTCTGCTATGCCTCA 9 6 0  
9 6 1  ATA A AATG CGTTAAAGCAAAAAAAAA
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corresponding to His57, Asp102 and Ser195 in chymotrypsin. The 
residues surrounding the active sites are highly conserved 
in serine protease, which is also true of the mouse 
tryptases.
The partial seguence of clone plT86, coding for 
tryptase I, is identical to the corresponding regions of 
plT4, except that an additional 119 nucleotides are present 
within the codon for Pro<B (see figure 15). This seguence 
was not present in any other clone sequenced. At this 
position, three amino acids after the active site His 
residue, introns have been found in a group of other serine 
proteases, including trypsin (Craik et al., 1984), cytotoxic 
cell protein I (Lobe et al., 1988), RMCP II (Benfey et al., 
1987), human neutrophil cathepsin G (Salvesen et al., 1987), 
human glandular kallikrein (schedlich et al., 1987) and 
human tryptase (Vanderslice et al., 1990). The total 119 bp 
additional nucleotide seguence is shown below:
5'-GTGAGTCTCCCTGGGCCTGGCATGGTGGGACGGGATCTAGATTATTCCCACCATCCC 
CAGTGTTCCCGAGGATGTGCCCATCCTGGCTGGAGCTTCTGAGCATGATTATACTCTTCT 
AG-3'.
The double- and single-underlined hexanucleotide sequences 
at the 5' and 3* termini, respectively, of this region are 
consensus sequences for intron/exon splicing junctions
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(Breathnach and chambon, 1981). This suggests that this 
seguence most likely represents an unspliced intron or an 
intron remnant.
Neither of the cDNAs for the tryptases were isolated as 
full length. The 51 nucleotide sequence of tryptase I did 
not contain an ATG codon for a Met residue, which could have 
served as a translation initiation signal. Although an in­
frame ATG codon exists in the -5 position in tryptase II, it 
is doubtful that it serves as a translation initiation site. 
By analogy to the signal peptides of dog and human tryptases 
(Vanderslice et al., 1989; Miller et al., 1989), the mouse 
tryptases are expected to have signal peptides of 30 amino 
acids. Therefore, the 29 and 22 amino acid peptides at the 
5* ends of tryptase I and tryptase II, respectively, 
represent partial leader peptide sequences for the mouse 
tryptases. These leader peptides are only 55% identical to 
each other with regard to amino acid sequence as compared to 
70% identity for the catalytic region. The nucleotides 
coding for the leader peptide sequence of tryptase II are 
69% identity with the corresponding sequence of tryptase I.
Molecular Cloning of Mouse Mast Cell Chvmase
Chymotryptic activity in ABFTL-6 cell extracts was 
detected at a very low level using the synthetic 
chymotryptic substrate Boc~(Ala)2-Pro~Phe-pNA (data not 
shown). However, the ABFTL-6 cell RNA slot-blot probed with 
a rat mast cell chymase II (RMCP II) cDNA revealed a high
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Figure 17. Mouse mast cell RNA slot-blot hybridization 
analysis for chymase-encoding sequences. This RNA slot blot 
is the same used for dog tryptase cDNA hybridization as 
described in Figure 12. Hybridization was carried out at 
standard stringency with labeled RMCP II cDNA as probe. (A) 
Formaldehyde denatured RNA; (B) NaOH-treated RNA; (c) NaOH- 
treated mouse genomic DNA. Lane 1 and 2 contain 1 and 3 fig 
RNA, respectively. Row a and b contain 0.4 and 2 fig DNA, 
respectively.
level expression of chymase RNA (Figure 17). These results 
indicate that ABFTL-6 cells may contain significant chymase 
activity and that better enzyme substrates are needed for 
detecting and measuring this activity. The strategy used 
for cloning mouse chymase cDNA was the same as that employed 
for the tryptase cDNA (see Figure 3). Initial screening of 
the cDNA library was with the insert of RMCP II, which 
identified 15 hybridization-positive clones. Eight of these 
were plague-purified and their DNA isolated. The inserts, 
released by EcoRI cleavage, ranged in size between 400 and 
600 bp. Seven clones (/2, 3, 4, 5, 8, 9, and 10) were 
subcloned into pTZ19U plasmid for sequence analysis. The 
compiled sequences revealed that the inserts code for a 
carboxyl terminal sequence of a novel chymase. Clone #3 
insert DNA was then used as a probe in rescreening the 
original cDNA library (1 X 105 recombinant phages). 
Hybridization-positive chymase plaques were found at a 
frequency of -0.5%, which is similar to that found for the 
tryptase cDNA. Of the 120 partially plaque-purified 
positives, nineteen were selected for detailed analysis 
based on plaque hybridization intensity. The size of their 
inserts ranged from 600-1500 bp. Seven of the larger 
inserts were subcloned for sequence analysis. Similar to 
the tryptase cDNAs, the sequences obtained fell into two 
groups each encoding a previously undescribed mouse mast 
cell chymase. The first group consisted clones plC19, 26,
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and 51.1, and was designated as mouse mast cell chymase I. 
The second group included plC51, 127.1, and 102, with 
sequences identical to those of the previously isolated 
group of chymase clones including plC3. This second group 
was designated as mouse mast cell chymase XI.
Clones pA,C26 and pAci02 are the representatives of 
mouse chymase I and II, respectively. The Hindlll and PstI 
restriction fragments of chymase I and the AccI, Rsal and 
Hindlll restriction fragments of chymase II were subcloned 
for sequencing. Ninety five percent of the sequence data 
were verified by sequencing the complementary strand or 
independent recombinants. The subcloning and sequencing 
strategies for these two chymase cDNAs are presented in 
Figures 18 and 19.
The consensus nucleotide and the derived amino acid 
sequences of mouse chymase I are shown in Figure 20. 
Translation starts at an ATG initiation site codon (base 6), 
and stops at the TAG stop codon (base 747) in the same 
reading frame. The open reading frame is preceded by 5 
bases of a 5' untranslated region. There are 211 
untranslated bases located after the stop codon. The 
translated form of mouse chymase I consists of 247 amino 
acids including a characteristic hydrophobic signal peptide 
of 21 amino acids. The mature form of the enzyme contains 
226 amino acids with a calculated Mr of 25.4 kd. Hisw ,
Asp89, and Ser182 of the deduced chymase sequence correspond
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Mouse Chymase I
- - o  -  200 bp
CO ~  CO _____
CL X  CL . . .
-H-- 1----- Mn
pxC26
*•----- H
P>jC51.1 f
pXC19
Figure 18. Strategy for subcloning and sequencing mouse 
chymase I cDNAs. The rectangle represents the open reading 
frame of the cDNA. The hatched and open areas show the 
regions encoding the putative signal/activation peptide and 
the active chymase, respectively. The lines attached to 
rectangles designate the 5* or 3'-noncoding region. The 
lines with arrows indicate the length and direction of 
nucleotide sequences obtained by dideoxnucleotide sequencing 
of the cDNAs and their subfragments.
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Mouse Chymase 11
E  S '  2 0 0 b P
8  .e  8  8  ---------
lu X  CC <  /  a \
1------- 1— I— I---------- <A>n
pxC102
pX C51
pX C 3 I--------1-
(pXC 1 -  9)  ~
Figure 19. Strategy for subcloning and sequencing mouse 
chymase II cDNAs. The open rectangle represents the open 
reading frame of the cDNA. The shadowed areas show the 
regions encoding for the putative intron sequence. The 
lines attached to rectangles represents the 3'-noncading 
region. The lines with arrows indicate the length and 
direction of nucleotide sequences obtained by 
dideoxnucleotide sequencing of the cDNAs and their 
subfragments. Notice that the EcoRI site at the 5' end of 
the sequence is an internal site. The nucleotide sequences 
of pic 1 through 9 are identical to plC3.
Figure 20. The composite cDNA's nucleotide and derived 
amino acid seguence of mouse mast cell chymase I. The 
numbers on both sides of the sequence indicate nucleotide 
positions. The amino acid sequence deduced from the cDNA is 
shown in single-letter code above the first nucleotide of 
each codon, and are numbered above every tenth residue.
Amino acid residues -21 to -1 represent the 
signal/activation peptide. The amino acid residues which 
comprise the catalytic triad (Hisw , Asp89 and Ser182) are 
marked with stars. The solid square labels the residue 
(Asn176) in the substrate-binding pocket. The potential N- 
linked glycosylation site (Asnw ) is marked with a dot. The 
putative polyadenylation signal sequence is underlined.
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Houso c h y m a s e - I
-20  -10
M W L L T L I I L L L L L L G S S T K A  
1  AGAGGATGCATCTTCTTACTCTTCATCTG CTG CTCCTTCT CCTGGGTTCCflGCACCAAAG
-1 +1 10
G E I I G G T E C I P I I S R P Y M A Y L  
C1 CTGGAGAGATCATTGGAGGCACGGAGTGCATACCACACTCCCGCCCCTACATGG CCTATC
2 0  3 0
E I V T S E N Y L S A C S G F L I R R N  
1 2 1  TGGAAATTGTCACTTCTGAGAACTACCTGTCGGCCTGCAGTCGCTTCCTGATAAGAAGAA
40 ★  SO
F V L T A A I I C A G R 5 I T V L L G A 1 1  
1 0 1  ACTTTGTCCTGACTC CAG CTCACTGTCCCCGAACGTCTATAACAGTCCTCCTAGGAGCCC
•  6 0  7 0
N K T S K E D T W Q K L E V E K Q P L H  
2 4 1  ATAACAAAACATCTAAAGAAGACACGTGGCAGAAGCTTGAGGTGGAAAAGCAATTCCTTC
0 0  ★  9 0
P K Y D E N L V V I I D I M L L K L K E K  
3 0 1  AT C CAAAATATGATG AGAATTTG GTTGTCCACGACATCATGCTACTGAAGTTGAAGGAGA
100 110
A K L T L C V C T L P L S A N F N F X P  
3 6 1  AAGCCAACCTAAC C CTAGGTGTGGGAACCCTCCCACTCTCTGCCAACTTCAACTTTATCC
1 2 0  1 3 0
F C R M C R A V G W G R T N V N E P A S  
4 2 1  CACCCGGGAGAATGTGCAGCGCAGTTCGCTGGGGCAGAACAAACCTGAATGAGCCAGCCT
1 4 0  1 5 0
D T L Q E V K M R L Q E P Q A C X H F T  
4 0 1  CCG ACACA CTG CAG GAAGTAAAGATGAGACTCCAGGAGC C CCAAG C CTG CAAACACTTCA
1 6 0  1 7 0  B
S F R I I H S Q L C V G N P K X H Q H V Y  
5 4 1  CCAGTTTTCGACACAATTCCCAGCTGTGTGTGGGCAACCCCAAGAAGATGCAAAATGTAT
1 0 0  ★  1 9 0
K G D S G G P L L C A G I A Q G I A S Y  
6 0 1  ACAAGGGAGACTCTGGAGGACCTCTGCTGTGTGCTGGGATAGCCCAAGGCATTGCATCCT
200 210
V H R H R K P P A V F T R I S H Y R P W  
6 6 1  ATGTACATCG GAAT CGAAAC CC CC CTG CTGTCTTTA C CAGAATCTCC CATTACAGGCCCT
220
I N K I L R E W  End  
7 2 1  GGATCAATAAGATCTTGAG G GAG AATTAACTCTG GAG CTTTTG C CAG C CTGTGAG G AAAT 
7 0 1  CTGGAACTGGAATAGTGCAGGTTTTGTGTGCCATGCGATCTGGCCTGTCTGTAGTTCCTG 
0 4 1  CTGAAGCCCTGCCTGGTCCCTGAGCTTCCAGAAGGTTCTTACAAGTCACAGAATGTTCCT 
9 0 1  AAAAGCCACCATCTTCATTAACCTCAATAAAGACCCAGATTCTCAACTGCAAAAAAAAAA
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120
100
2 4 0
3 0 0
3 6 0
4 2 0
4 0 0
540
6 0 0
6 6 0
7 2 0
7 0 0
0 4 0
9 0 0
9 6 0
to the active-site residues His57, Asp102, and Ser195 in 
chymotrypsinogen which are essential for the proteolytic 
activity of all serine proteases (Fersht, 1977). Residue 
Asn176 is present in the substrate binding pocket suggesting 
an unusual substrate specificity, because this residue has 
not been found at this position in other serine proteases.
A potential N-linked glycosylation site is present at amino 
acid residue Asn59. Based on the number of basic (Arg + Lys 
=23) and acidic (Asp + Glu = 20) amino acids, the mature 
enzyme is positively charged at pH 7.4.
The consensus nucleotide seguence obtained from mouse 
chymase II clones consists of 1009 nucleotides and includes 
an exceptionally long poly (A)+ tail of 46 bases. The 
seguence contains 227 and 253 bases of 5' and 3* 
untranslated regions, respectively. Amino acid seguence 
analysis of the long open reading frame revealed that it 
represents the carboxyl terminal of a different chymase 
which shares 52% seguence identity with the corresponding 
region mouse chymase I. The nucleotide and derived amino 
acid sequences of chymase II are presented in Figure 21.
The protein seguence comprises 175 amino acid residues and 
begins at the third exon of most known serine proteases. 
Most likely the 5'-end 227 base noncoding region represents 
an unspliced intron sequence since there is a highly 
conserved intron/exon junction at this location in the 
serine protease superfamily (Benfey et al., 1987;
Figure 21. The consensus nucleotide seguence of mouse mast 
cell chymase II cDNA and its derived amino acid seguence.
The numbers on both sides of the seguence indicate the 
nucleotide positions. The amino acid seguence deduced from 
the cDNA is shown in single-letter code above the first 
nucleotide of each codon, and are numbered above every tenth 
residue. The underlined nucleotides represents the putative 
intron seguence. The active site amino acid residues Asp89 
and Ser182 are marked with stars. The solid square labels 
the residue (Ser176) in the substrate-binding pocket. The 
two potential N-linked glycosylation sites (Asn82 and Asn100) 
are marked with a dot. The amino acid residue numbering 
follows that for mouse chymase I (Figure 20) under the 
assumption that mouse chymases I and II have similar primary 
structure.
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H o u s e  C h y m a so  I I
1 AAGACATCGCAAAGCACTGAAGCATGCTCGGAAATGGGTCCTTTCCCAGTHNTCCTTAAT GO
6 1  CACATAGAATTCAGGATTGGGTTCTGAGGAAAAGGATTGGGCAAGAOAGAATTCAAAGAC 1 2 0
1 2 1  CCGAGTCGGGACGAGAGTTAAGCATGGGAGACTTAACCAGGGCAAAATAAGGCCACCTTG 1 0 0
SI
M T V T
1 0 1  AG TA ACATG ATGT CATGG AG CTTGGA A G AG A A GTTGTATTTTGGAAGAATGACTGT CACT 2 4 0
6 0  7 0
L G A H N V R K R E C T Q Q K I K V E K  
2 4 1  CTTG GAG CTCATAATGTG AG AAAGAGAGAATG CACACAG CAGAAGATAAAAGTTGAAAAG 3 0 0
0 0  o  ★  9 0
Y I I i P P N Y N V S S K F N D I V L L K  
3 0 1  TACATCTTG C CT CCAAATTACAATGTGT CTTCCAAGTTCAATGACATCGTATTA CTG AAG 3 6 0
100 110
L E K Q A N L T S A V D V V P L P A P S  
3G 1 CTTGAAAAG CAAGCTAACTTGACTTCTGCTGTGGATGTAGTTCCCCTGCCTGCCCCCTCT 4 2 0
1 2 0  1 3 0
D F A K P G T M C W A A G W G R T G L K  
4 2 1  GACTTTGCCAAGCCTGGGACGATGTGCTCGGCAGCTGGCTGGGGGCGAACTGGATTGAAA 4 0 0
14 0 1 5 0
K S X S R T L R E V E I i R X M G K K A C  
4 0 1  AAAAGTATCTCACGTACCCTGAGAGAGGTAGAACTGAGAATCATGGGGAAAAAGGCCTGT 54 0
1 6 0  1 7 0
K X F K H V K D S L Q I C V G S S T K V  
5 4 1  AAAATATTTAAG CATTACAAGGATA GCCTCCAGATCTGTGTGGG CAGTTCCACAAAGGTG GOO
■  1 0 0  ★  1 9 0
A S V Y M G D S G G P L X . C A G V A I I G  
6 0 1  G CATCAGTATACATG G GAG A CTCTGGAGGACCTCTACTGTGTG CTGGGGTGGCCCATGGT 6 6 0
200 210
I V S S G R G H A K P P A I F T R I S P  
6 6 1  ATTGTAT CTTCTGGACG CG GAAATG CAAAG CCCC CTG CAAT CTT CAC CCGAATCTCCCCA 7 2 0
220
H V P W I N R V I E G K  End  
7 2 1  CATGTGCCCTGGATTAA CAG AGT CATAGAG G G CAAGTAGTG AAAA G CCTGACCTGCGTGC 7 0 0
7 0 1  ATCAGAGTCTTCAAGCCAGAGCTCTTCTGATAACCCTTGGGTTCAACAAAGGATGTGTCC 0 4 0
0 4 1  ATCCTGTCCCCTGCCTGCCCCCAGCATGTCCCTAGCATGTCCCCCGCCTGCCCTCAGCCT 9 0 0
9 0 1  GCCCCCAGTCTGTCCCCAAGATGATCTGAJVAAATAAAGTCTGTGATGATGGACTGTTCCC 9 6 0
9 6 1  TGTAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 1 0 0 9
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Vanderslice et al., 1990). Introns at this position, 4 
amino acid residues after the active site histidine, are 
found in all known serine proteases. In the exact same 
position, an intron has been found in one mouse tryptase I 
clone, pJLT85 (see Figure 15) , Furthermore, a putative 
intron/exon junction sequence (TGGAAG) is located at the 3' 
end of the proposed intron sequence.
DNA sequence analysis shows that there is no EcoRI/Notl 
adopter sequence at the 5' end of the plasmid insert. This 
indicates that the EcoRI site used to subclone this segment 
from the original 1C102 cDNA insert is an internal 
restriction site within the intron sequence (see Figure 19). 
Therefore, this subcloning step eliminated the 51 end of 
this cDNA from subsequent analysis.
Northern and Southern blot analysis
To study the tissue specific expression of tryptase and 
chymase in mouse tissues and mast cells, and to investigate 
the size of their primary transcripts, a Northern blot 
hybridization analysis was performed as shown in Figure 22. 
Poly(A+) RNA from ABFTL-6 mouse mast cells, tongue and 
intestine tissues were prepared and blotted onto a Nytran 
membrane. When this blot was probed with a chicken o- 
tubulin cDNA as a control hybridization, positive signals 
were present in all three samples (Figure 22, panel A). 
However, hybridization of the same blot with the plT4/DraI 
5' fragment of tryptase I (see Fig. 14) revealed that
A B C
Figure 22. Northern blot hybridization analysis for 
tryptase and chymase expression. Purified poly(A)+ RNA from 
mouse tongue (6 fig, lane a), intestine (6 fig, lane b), and 
ABFTL-6 mouse mast cells (2.4 fig, lane c) were fractionated 
on a formaldehyde-containing 1.5% agarose gel and blotted 
onto a nitrocellulose membrane. The blot was sequentially 
hybridized with a chicken a-tubulin (Panel A) , plT4/DraI 5 1 
fragment (tryptase I; Panel B), and pAC3 insert DNA (mouse 
chymase II; Panel C). All probes were ^P-labeled by the 
random primer method and hybridized to the filter under 
standard hybridization conditions. The size of molecular 
weight markers are indicated to the left.
tryptase RNA was detectable only in the mast cells and, at 
much lower levels, in the tongue tissue. No hybridization 
was detectable from the intestine RNA (Figure 22, panel B). 
Using piC3 insert (chymase II) as a probe, strong 
hybridizations were found in both the mast cells and tongue 
tissue. A barely detectable level of chymase hybridization 
to the intestine RNA was noticed also (Figure 22, panel c). 
Tongue is known as a CTMC-rich tissue, and has been used as 
a good source for mast cell chymase isolation (Kido et al., 
1984). However, tongue also contains many other cell types. 
Thus, the intensive hybridization observed in tongue 
poly(A)+ RNA indicates that the relative level of chymase 
expression in the tongue is extremely high, chymase 
expression is much higher than that of tryptase in tongue 
tissue as judged by comparing the tryptase and chymase 
hybridization intensities with those of ABFTL-6 poly(A)+
RNA.
The average sizes for tryptase and chymase primary 
transcripts, estimated from the Northern blot, are 1250 and 
1150 bases, respectively. This suggests that the cDNA 
clones isolated for mouse tryptases and chymases lack a 
portion of 5* region.
A Southern blot hybridization analysis was performed to 
study mouse tryptase gene structures. The plT4/DraI 5' 
fragment and a mouse tryptase II synthetic oligonucleotide 
were used as probes of a mouse genomic DNA blot as shown in
in Figure 23. These two probes are gene specific for mouse 
tryptase I and II, respectively. Comparison to the dog 
tryptase gene structure suggests that these probes should 
not contain an intron/exon junction site (Vanderslice et 
al., 1990). The plT4/DraI 5' fragment is 90 bp long, 
corresponding to nucleotides from bases 57 to 147 of mouse 
tryptase I cDNA (see figure 15). Although this fragment has 
72% sequence identity to mouse tryptase II in the 
corresponding region, it will not cross-hybridize to 
tryptase II since 83% sequence identity is required for 
positive hybridization under the standard conditions. The 
mouse tryptase II oligonucleotide sequence was derived from 
base 19 to 45 of mouse tryptase II cDNA and shares 67% 
sequence identity to tryptase I in the corresponding region.
As shown in Figure 23, a single band was detected in 
each lane, regardless of which restriction enzyme was used. 
Moreover, the two mouse tryptase gene-specific probes 
exhibited different hybridization patterns. These results 
suggest that each mouse tryptase is probably encoded by a 
single gene.
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Figure 23. Southern blot analysis of tryptase genes in 
mouse genomic DNA. House genomic DNA (15 fig) was digested 
with restriction enzyme and separated on a 1.0% agarose gel. 
The gel was stained with EBr to display the fragment 
distribution pattern of the total DNA (panel A), and the DNA 
was blotted onto a Nytran hybridization membrane. The blot 
was hybridized sequentially with the [a-32P]-labeled 
plT4/Dral 5' fragment of tryptase I under standard 
hybridization conditions (panel B) and [y-32P]-5'-end- 
labeled mouse tryptase II specific oligonucleotide in 3 X 
SSPE, 1% SDS and 20% formamide at 42°C (panel C). The size 
(kb) and location of molecular weight markers are indicated 
to the right of the panels. The restriction enzymes used to 
digested the DNA are indicated on the top of each figure. 
They are: E, EcoRI; H, Hindlll, K, Kpnl; P, PstI; T, TaqI;
B, BamHI; R, Rsal; X, Xbai; The sequence of neither probe 
contains any restriction site for those restriction enzymes 
used to digest the mouse genomic DNA.
CHAPTER 4 
Discussion
Growth of ABFTL-6 Mouse Mast Cells in FCM 
The ABFTL-6 mouse mast cell line used in these studies 
was derived from fetal mouse liver in the presence of IL-3 
and transformed with Abelson murine leukemia virus (Pierce 
et al., 1985). Although the transformed cells no longer 
require IL-3 for growth, they retain other characteristics 
of mast cells derived from hemopoietic tissues. They are 
small in size, contain few cytoplasmic granules and a low 
level of histamine (Pierce et al., 1985). They are 
considered representative of the MMC in vivo (Katz et al., 
1985; Katz and Austen, 1987).
It has been reported that the viability and the CTMC 
phenotype of purified rat peritoneal mast cells and human 
lung mast cells could be maintained for prolonged periods in 
vitro if the mast cells were co-cultured solely with mouse 
3T3 fibroblast cells (Levi-Schaffer et al., 1985; Levi- 
Schaffer et al., 1987a). Co-culture with 3T3 fibroblasts 
also induced in vitro-differentiated. IL-3-dependent mouse 
mast cells to change phenotype from mucosal-like to 
connective tissue-like mast cells (Dayton et al., 1988; 
Levi-Schaffer et al., 1986; 1987b). More recently, Jarboe 
et al. (1989) have identified mast cell-committed progenitor 
cells from the mesenteric lymph node of mice infected with
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Nippostroncrvlus brasillensis. These progenitors are able to 
proliferate and differentiate into CTMC-like cells when 
cultured on a fibroblast monolayer or in conditioned media, 
and into MMC-like cells when cultured in the presence of 
ID-3,
The results of this study have shown that cell-free,
3T3 FCH can induce phenotypic change of the ABFTL-6 mast 
cells. No direct contact between fibroblasts and mast cells 
was necessary. The results have also demonstrated that, 
like mast cells from other species, these mouse mast cells 
contain a tryptase which exhibits an inhibition profile 
similar to that of dog and human tryptases (smith et al., 
1984? Caughey et al., 1987; Butterfield et al., 1990).
Also, the mouse tryptase is immunoreactive to human tryptase 
antibody suggesting a similarity between their primary 
structures.
ABFTL-6 mouse mast cells undergo phenotypic changes 
upon culturing in media supplemented with FCM. The induced 
mast cells increased in size, had larger and more 
cytoplasmic granules which stained intensely with toluidine 
blue, and increased the total cellular protein about four­
fold. FCM induced an increase in tryptase enzymatic 
activity in ABFTL-6 cells about 13-fold. However, immuno­
reactive tryptase protein increased by 54-fold. The induced 
cells contained 125 fig tryptase per 106 cells based on 
immunoassay using antibodies to human tryptase, which is
much higher than the 35 /ig/106 cells found in human mast 
cells from adult foreskin (Schwartz et al., 1987). Total 
DFP-binding proteins were also increased to much higher 
levels (Figure 11). Most interestingly, the ratio of 
tryptase to the total cellular protein has increased 
dramatically, from 2.7% in uninduced cells to 38% in induced 
cells. This tryptase level in the induced cells is 
considerably higher than previously estimated for human lung 
mast cells (23%) and for chymase, the predominant neutral 
protease in rat mast cells (25%) (Schwartz et al., 1981a).
At present, the data does not allow a determination of 
whether these changes reflect the maturation process or the 
further differentiation of ABFTL-6 cells from MMC-like to 
CTMC-like. However, the latter possibility is more likely 
since the importance of fibroblasts or a connective tissue 
micro-environment in the development and maintenance of CTMC 
is well established (Galli, 1990).
Several mast cell growth factors have been identified 
in recent years. Survival and growth of in vitro- 
differentiated hemopoietic tissue "MMC-like" mast cells 
strictly depends on IL-3. IL-4 acts in synergy with IL-3 in 
the proliferation of "MMC-like" mast cells and also appears 
to be essential for "CTMC-like" mast cell growth in vitro 
(Hamaguchi et al., 1987; Ihle et al., 1983; Nakahata et al., 
1986). The 3T3 fibroblasts do not produce detectable IL-3 
or IL-4 (Fujita et al., 1988). The nature of the fibroblast
factors involved in the induction of mast cell phenotypic 
changes remains to be determined. However, a soluble factor 
in FCM responsible for mast cell-1 committed progenitor cell 
differentiation and proliferation has been partially 
characterized (Jarboe et al., 1989). It appears to be a 
novel cytokine secreted by fibroblasts since its mast cell 
proliferation activity could not be mimicked by a wide 
variety of other growth factors, whether this is the same 
factor which promoted the observed differentiation of ABFTL- 
6 mouse mast cells is currently unknown. Recently, a new 
hematopoietic growth factor with a broad range of biological 
activity has been defined (Witte, 1990). This growth factor 
is known to influence hematopoietic stem cell development, 
including those for mast cells.
Sodium_Butvrate_lnduction of Tryptase. Expression 
in ABFTL-6 Mouse Mast Cells 
Sodium butyrate has been known to increase the 
development of cytoplasmic granules and the storage of 
granule-associated mediators in mouse mastocytoma cells. In 
the presence of butyrate, histamine content increased 
concomitant with cytoplasmic granule maturation and exceeded 
that of untreated mast cells by 140-fold (Mori et al.,
1980). This effect of butyrate has been confirmed in mouse 
BMMC (DuBuske et al., 1984). In addition, butyrate-treated 
mast cells increased the cellular levels of [3H] DFP-binding 
protein twofold and cytoplasmic granule-associated tryptic
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activity fourfold. However, variation of the effectiveness 
of butyrate induction has been noticed among different 
clones of mast cells (Mori et al., 1980). Sodium butyrate 
failed to induce synthesis of heparin in vitro-cultured MMC- 
like mast cells (DuBuske et al., 1984). This is a major 
difference between butyrate and FCM induction.
Sodium butyrate exhibited a tryptase induction effect 
on ABFTL-6 mouse mast cells similar to the FCM. Besides the 
morphologic changes, the butyrate-induced cells increased 
total cellular protein content three-fold and tryptase 
activity six-fold. Surprisingly, tryptase protein content 
measured by immunoassay using antibodies to human tryptase 
increased from 2.3 /ig/106 cells to 75 fig/106 cells, a 32- 
fold increase (refer to Table 2 in Results). The ratio of 
tryptase to the total cellular protein increased to 28% from 
2.7%. This result is in agreement with those previously 
reported concerning the effect of butyrate on cultured mast 
cell granules-associated serine proteases. However, it also 
indicated that tryptase production by ABFTL-6 mast cells was 
more sensitive to butyrate induction than that reported by 
the BMMC (DuBuske et al., 1984).
While the precise mechanism by which butyrate induced 
tryptase synthesis and other phenotype changes is obscure, 
it is known that butyrate causes hyperacetylation of histone 
protein by inhibiting the deacetylase enzyme (Riggs et al., 
1977; Candido et al., 1978). This modification of histones
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is coupled with an increased transcription (Allfrey et al., 
1964). Butyrate can increase methylation of histone, and 
increase the activity of cell membrane-bound enzymes 
including alkaline phosphatase and adenylate cyclase 
(Simmons et al., 1975; Henneberry and Fishman, 1976).
Endogenous Tryptase inhibitor in Hast Cells
Since tryptase is stored and released in its fully 
active form, unlike pancreatic proteases, it is a potential 
hazard to its host cells. Thus, it is reasonable to assume 
that tryptase activity may be regulated by certain protease 
inhibitors which co-exist with tryptase within mast cell 
granules. An endogenous rat serine protease inhibitor, 
named trypstatin, has been well characterized and its amino 
acid sequence determined (Kido et al., 1985 and 1988). 
Trypstatin associates with tryptase in granules of rat 
peritoneal mast cells and forms a complex in a molar ratio 
of 1:1 with each subunit of tryptase. Trypstatin strongly 
inhibits tryptase and blood coagulation factor Xa. It also 
inhibits porcine pancreatic trypsin and rat chymase (Kido et 
al., 1988). Although one would expect that the expression 
of trypstatin may be a universal feature of mast cells, this 
type of inhibitor has not been identified in mast cells of 
any other species.
Whether there is a trypstatin-like tryptase inhibitor 
present in mouse mast cells and how it would be affected by 
tryptase-inducing agents are entirely unknown. However, the
results of our induction experiments revealed that the 
increases in tryptic activity and tryptase antigen levels 
were not directly proportional. For example^ while tryptase 
antigen increased about 54-fold in FCM induced cells, the 
tryptic activity only increased 13-fold. These results 
invite speculation that there may be a tryptase inhibitor in 
ABFTL-6 mouse mast cells, and that this inhibitor may be 
induced in parallel with the tryptase. An alternative 
explanation may be that FCM or butyrate might induce the 
synthesis of proteins that share some antigenicity with 
tryptase, but lack proteolytic activity, or have different 
substrate specificities.
Trvotase Processing 
Both mouse tryptases clearly have leader sequences 
which must be removed prior to the generation of active 
enzymes with the classic N-terminal sequence Ile-Val-Gly-Gly 
found in many serine proteases (Figure 24). As noted by 
Vanderslice et al. (1989), the tryptases are the first 
family of proteins to have Gly in the -1 position. While 
the active enzyme could be generated via signal peptidase 
cleavage after Gly'1, this is doubtful because there are no 
reported instances of signal peptidase cleavage with Arg or 
Lys in the -3 position (von Heijne, 1986). Another possible 
signal peptidase cleavage site is Ala'6 which is conserved 
in the four known tryptases and is Leu in dog mast cell 
protease. However, this would also result in an Arg residue
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Figure 24. Alignment of leader sequences of the mouse 
tryptases and other related proteases. The proposed sites 
for cleavage of the signal and activation peptides are shown 
by arrows. Numbering across the top refers to the leader 
peptide sequences, whereas numbering across the bottom 
refers to the proposed signal peptide sequences.
(Arg'9) in the -3 position relative to Ala"6 of mouse 
tryptase I. This diminishes the likelihood of Ala'6 being 
the processing site. A more likely site of cleavage is 
the -4 position which contains Gin in three of 
the sequences, with Thr'* in mouse tryptase II and Pro'* in 
dog mast cell protease. Gin, Thr, and Pro residues have 
served as processing sites in eukaryotes and this choice 
results in Ala*6 being in the -3 position of all four 
tryptases. Ala is the most favored residue in this position 
(von Heijne, 1986). Dog mast cell protease has a Leu'6 in 
the -3 position relative to the proposed signal peptidase 
cleavage site, which is not as highly favored as Ala in 
the -3 position. However, this places Ser'5 in the -2 
position and Ser is the most favored residue in the -2 
position (von Heijne, 1986). Signal peptidase processing at 
the -4 positions in the leader peptide sequences as shown in 
Figure 22 would leave zymogens with propeptides of three 
residues consisting of Arg-X-Gly, Lys-X-Gly in all cases, 
except for Gln-X-Gly in human tryptase. Although human 
tryptase would not have a basic residue for its zymogen form 
amino terminus, a polar Gin residue with a charged alpha 
amino group would seem to be a plausible substitution at 
this position. A propeptide consisting of only two amino 
acids has been found in the leader sequences of the human 
neutrophil proteases cathepsin G and elastase (Salvesen et 
al., 1987; 1990). These are granule-associated, active
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enzymes also. Of course, it is possible that the processing 
and activation of the tryptase family involves unique 
cleavages and additional studies are needed to clearly 
understand these events.
Deduced Trvotase Structures
Analysis of the deduced amino acid sequence of mouse 
tryptase 1 revealed that it encoded the entire catalytic 
portion of the protease. The active enzyme consists of 245 
amino acids with a calculated molecular weight of 27,395 Da. 
A 29 amino acid-long partial leader peptide precedes the 
active enzyme. Tryptase II also contains a catalytic region 
of 245 amino acids with a calculated molecular weight of 
27,410 Da, and a partial signal peptide of 22 amino acids.
The lengths of the catalytic region of the mouse tryptases
are equivalent to that of dog tryptase (Vanderslice et al., 
1989), but they are one amino acid residue longer than human 
tryptase (Miller et al., 1989). The 280 nm extinction 
coefficients for 1% protein solutions calculated by the 
method of Gill and von Hippel (1989) are 25.1 and 24.2 for 
mouse tryptase I and mouse tryptase II, respectively. Human 
tryptase was found to have a value of 28.1 based on amino
acid analysis data (Smith et al., 1984).
There is little doubt that these two groups of cDNA 
clones code for two distinct mouse mast cell tryptases.
They share extensive sequence identity with the dog and 
human tryptases (Figure 25) and their leader peptides end
Figure 25. comparisons of the amino acid sequences of mouse 
tryptase active enzymes with the amino acid sequences of 
related proteases. The residue numbering follows the 
standard chymotrypsinogen notation. A single small dot 
represents an amino acid residue at that position identical 
to that of mouse tryptase I, and dashes indicate gaps 
introduced in order to achieve maximum homology. Stars 
indicate the active site residues His57, Asp102, and Ser195 
which compose the catalytic triad. The putative N-linked 
glycosylation sites are underlined, and the Asn linkage 
residue is marked with a dot. The number of residues in 
each enzyme is listed at the end of its sequence. Homology 
percentages relative to each mouse tryptase are given in 
parentheses. The sources of the sequence data are as 
follows: dog tryptase and dog mast cell protease (DHP) 
(Vanderslice et al., 1989), human tryptase (Miller et al., 
1989), bovine trypsin (Hartley, 1970) and bovine 
chymotrypsin (Blow et al., 1969).
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with a Gly residue prior to their Ile-Val-Gly-Gly sequences, 
as previously noted for mast cell tryptases (Vanderslice et 
al., 1989).
A comparison of the derived amino acid sequences of the 
active enzyme regions of the mouse tryptases to dog and 
human tryptases, dog mast cell protease, trypsin, and 
chymotrypsin is shown in Figure 25. Mouse tryptase I is 
most identical to dog tryptase at 74%, while mouse tryptase 
II is most identical to human tryptase at 73%. Mouse 
tryptases I and II are 41% identical to bovine trypsin, but 
if equivalent residues are considered the homology increases 
to 64 and 61%, respectively. The mouse tryptases are only 
distantly related to the proteases present in mouse 
cytotoxic T lymphocytes. For instance, mouse cytotoxic T 
cell protease I (Lobe et al., 1988) has only 36% and 35% 
sequence similarity to mouse tryptase I and II, 
respectively.
Both mouse mast cell tryptases have a potential N- 
linked glycosylation site at residue Asn113, the same 
location as in dog and human tryptases. Tryptase II, 
however, has an additional putative glycosylation site at 
Asn36. Human skin tryptases also shows differences in 
glycosylation. Human skin tryptases I and II contain two 
consensus N-glycosylation sites, whereas skin tryptase III 
only has one such site (Vanderslice et al., 1990). Assuming 
that the tertiary structures of mouse tryptase II
approximate the general topography o£ trypsin and 
chymotrypsin, both of these glycosylation sites would be 
positioned near each other at the top of the molecule when 
viewed with the substrate binding pocket facing and 
extending down to the right (Dickerson and Geis, 1969).
Such a finding provides additional support for the idea that 
tryptase heterogeneity, as seen on SDS-PAGE, is due in part 
to the extent of glycosylation (Cromlish et al., 1987). The 
catalytic regions of these two tryptases both begin with 
Ile-Val-Gly-Gly and exhibit all of the features 
characteristic of serine proteases. The active site 
"charge-relay" residues Hisw , Asp91 and Ser,M, corresponding 
to His57, Asp102 and Ser195 in chymotrypsin, are conserved.
The residues surrounding the active sites are highly 
conserved in serine proteases, which is also true of the 
mouse tryptases.
Eight cysteine residues are found in both tryptases I 
and IX, all of which are present in positions identical to 
eight of the ten cysteine residues of bovine trypsin. 
Presumably, these form disulfide linkages in the same 
arrangement as in trypsin. The absence of two disulfide 
linkages in these and other tryptases may result in 
decreased stability relative to trypsin. Interestingly, the 
mouse tryptases share the same eight cysteine residues with 
human tryptase; whereas, dog tryptase has nine cysteine
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residues. Dog mast cell protease differs considerably from 
the tryptases with twelve cysteine residues.
Trvntase Substrate Specificity Predictions 
The mouse tryptases are predicted to have trypsin-like 
specificities for Lys or Arg residues in the P., position of 
substrates, since an Asp is present in their substrate 
binding pocket (residues 188}, corresponding to the 
substrate binding pocket Asp189 in trypsin (Figure 26). The 
sidewalls of both mouse tryptase substrate binding pockets 
are lined with residues of Asp1B9-Ser190-Cys191-Gln192 and Ser2K- 
Trpzis-Glyz16 (chymotrypsinogen numbering system), an 
identical situation to that of dog tryptase and trypsin. In 
contrast, human tryptase has a Lys residue in position 192 
and an Asp instead of a Gly in position 216. Thus, the 
substrate specificities of the mouse tryptases may be in 
closer agreement with those of dog tryptase (or bovine 
trypsin) and may differ from the rather unusual 
specificities of the human skin and lung tryptases (Tanaka 
et al., 1983). Interestingly, residues in position 99 based 
on the chymotrypsin numbering system are Gly for tryptase I 
and Asp for tryptase II. This position influences substrate 
specificity with regard to the amino acid in position P2.
The differences at position 99 in the mouse tryptases 
suggest substrate specificity differences with respect to 
substrate specificity. An interesting feature of mouse 
tryptase I is that the lie103 in the highly conserved region
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around active site Asp102 is substituted by an equivalent 
amino acid Val103 (tryptase residue 92) in mouse tryptase I. 
While this substitution may not affect the enzyme's tertiary 
structure or function, Val in this position has never been 
observed in other members of the serine protease family.
Charged Residues of Tryptase
Mouse tryptase I is predicted to have a net charge of 
-5 at neutral pH, since it contains 23 acidic residues (Asp 
+ Glu) but only 18 basic residues (Arg + Lys).
Surprisingly, tryptase II is much more negatively charged 
than tryptase I, with a net negative charge of -10 at 
neutral pH (Asp + Glu *= 25, Arg + Lys 15). The estimated 
isoelectric points for mouse tryptases I and II are 6.2 and 
5.6, respectively. The charges on human and dog tryptases 
are -4 and -3, respectively, which are in closer agreement 
with mouse tryptase I than with mouse tryptase II. Thus, 
the tryptases are acidic proteins in contrast to the much 
more basic trypsin and chymotrypsin molecules with net 
charges of +3 and isoelectric points above 9. These charge 
differences probably account for the loss of activity noted 
with human tryptase at low pH (Smith et al., 1984); whereas, 
trypsin and chymotrypsin are quite stable at low pH.
Human tryptase activity is stabilized by heparin 
glycosaminoglycan (Smith and Johnson, 1984) and in the 
absence of heparin, tryptase subunits dissociate into 
inactive monomers (Schwartz and Bradford, 1986). Since the
Figure 26. Analysis of the distribution of charged 
residues that are conserved in tryptases. Two charged 
clusters are predicted. Near the top face of the molecule 
is a closely-associated, positively-charged cluster 
consisting of residues Lys26, Arg34, and Arg70 (shown in red) . 
Another cluster comprised of negatively charged residues 
Glu164, Asp169, and Asp177, forms a large patch along the lower 
face of the enzyme (shown in yellow). The active site 
residues His57, Asp102, and Ser159 are shown in green.
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interactions necessary for the formation of a tetramer may 
rely on the distribution of charge on the surface of the 
molecules, charged residues conserved among tryptases have 
been examined based on the tertiary structure of
i
chymotrypsin (Dickerson and Geis, 1969). Twelve charged 
residues (five positive and seven negative) are found to be 
conserved within the four tryptases shown in Figure 25, but 
are not found in the corresponding position of bovine 
trypsin. Assuming a folding pattern similar to that of 
chymotrypsin two charged clusters are predicted (Dickerson 
and Geis, 1969) as shown in Figure 27. One near the top 
face of the molecule is a closely-associated, positively- 
charged cluster consisting of residues 26, 34, and 70. The 
other, comprised of negatively charged residues 164, 169, 
and 177, forms a large patch along the lower side of the 
enzyme. Most of these charged residues seem to be displayed 
on the surface of the molecules. Of course, such charge 
distributions will require x-ray diffraction analysis for 
conformation, but these charges may be involved in the 
interactions among tryptase subunits or between tryptase and 
heparin.
Interestingly, charge-switching of residues between 
mouse tryptase I and mouse tryptase II is observed in four 
positions. Glu residues in positions 75, 107, and 244, in 
mouse tryptase I are substituted by oppositely charged Lys 
residues in mouse tryptase II, and Lys residue 204 of mouse
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tryptase I is substituted by a negatively charged Glu in 
mouse tryptase II. The charge switching also occurs between 
tryptases and other serine proteases such as trypsin. For 
example, Lys60 of trypsin, which is believed to form a salt 
bridge with Asp1 of soybean trypsin inhibitor in the 
trypsin-inhibitor complex (Sweet et al., 1974), is 
substituted with Gly in dog tryptase and mouse tryptases. 
This may be one of the reasons why tryptases are resistant 
to inhibition by soybean trypsin inhibitor (Vanderslice et 
al., 1989).
An unusual charge switching between tryptases and 
pancreatic serine proteases such as trypsin and chymotrypsin 
occurs at position 169. Lys residue is present at position 
169 in trypsin and chymotrypsin, while an oppositely charged 
Asp is found in the identical location in all known 
tryptases. This significant charge difference may 
contribute to the unique biochemical properties of tryptase, 
such as resistance to inhibition by a-l-FI and selectivity 
for natural substrates. Further investigation is needed to 
understand the significance of this charge-switching.
Characterization of the Predicted Protein structures 
of Mouse Mast Cell Chvmases 
All .of the active enzymes of the chymase class start 
with residues Ile-Ile-Gly-Gly. Thus, the 21 amino acids 
prior to this sequence in mouse mast cell chymase I is 
expected to be a complete leader peptide. This is supported
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Figure 27. Hydrophobicity analysis of mouse mast cell 
chymase I. Hydrophobicity analysis was performed by the 
Hopp and Woods method (1981), using the Hitachi PROSIS 
protein analysis program. Each amino acid is assigned a 
numerical hydrophobicity value. The more hydrophobic an 
amino acid is, the more negative its value. The x-axis 
indicates the position of amino acid in the protein 
sequence. The y-axis represents the hydrophobicity index 
ranging from 2 to -2. The full length of mouse chymase I is 
247 amino acid residues, including a 21 amino acid leader 
peptide.
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M. Chymase I 
Dog Chymase 
MMCP XI 
RMCP II 
H. Cat. G 
H. Elastase 
M. Granzyme C 
M. Granzyme G 
Mouse CCP I 
Mouse CCP II
 leader sequence----
-21 -3 -1 +1
! | | j
MHLLTLHLLLLLLGSSTKA GE IIGG*«
MHCLPLTLLLLLLCSRAEA EE IIGG*«
MQALLFLMALLLPSGAGA EE IIGG»*
MQALLFLMALLLPSGAGA EE IIGG»«
MQPLLLLLAFLLPTGAEA GE IIGG««
MTLGRRLACLPLACVLPALLLGGTALA SE IVGG»«
MPPVLILLTLLLPLRAGA EE IIGG»«
MPPILILLTLLLPLRAGA EE IIGG»*
MKILLLLLTLSLASRTKA GE IIGG**
MPPVLILLTLLLPLRAGA EE IIGG*»
-18
Ii
-1
•signal------ t-pro-t-active-
Figure 28. Comparison of the mouse chymase I leader 
sequence with those of other known chymases and granule- 
associated serine proteases. Numbering across the top 
refers to the leader peptide sequences, and numbering across 
the bottom indicates the signal/activation sequence. The 
source of the sequence data is as follows: dog chymase 
(Caughey et al., 1990)? MMCP II (Serafin et al., 1990); RMCP 
II (Benfey et al., 1987); human cathepsin G (Salvesen et 
al., 1987); human elastase (Takahashi et al., 1988); mouse 
granzyme c (Jenne and Tschopp, 1988); mouse granzyme G 
(Jenne et al., 1989); mouse CCP-I and CCP-II (Lobe et al., 
1988). The abbreviations used are: M, mouse? H, human; cat. 
G, cathepsin G; CCP, cytotoxic cell protease.
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by the amino acid hydrophobicity analysis. As shown in 
Figure 27, a large hydrophobic domain is present within that 
leader sequence. The length of this leader peptide is 
identical to that of dog chymase, but one amino acid longer 
than that of MMCP II, RMCP II, and other granule-associated 
serine proteases listed in Figure 28. As shown in this 
figure, the leader sequence of mouse chymase I contains many 
features common to those enzymes, and has 57% sequence 
identity to that of dog chymase.
Based on the "-3, -I1' rule of von Heijne (1986), it is 
predicted that the signal peptidase cleavage site for mouse 
chymase I signal peptide would be between Ala*3~Gly*2, since 
Ala is the most favored residue in -1 position for peptidase 
cleavage. After removal of the signal peptide, mouse 
chymase I exists as a zymogen form containing a "pro" 
peptide of two amino acids (Gly-Glu). This predicted 
preprosequence is very similar for all the known chymases, 
human cathepsin G, elastase and mouse lymphocyte granule 
serine proteases (granzymes) listed in Figure 26. The 
highly conserved residues Glu‘z and Ala*5 within the leader 
sequence were replaced with Gly*z and Thr*5 in mouse chymase 
I, respectively. However, Gly in -2 position is also found 
in human cathepsin G and mouse cytotoxic cell protease (CCP)
I. Threonine, a preferred residue in -5 position for 
cleavage, is located at the identical position in mouse CCP
II. Recently, the existence of a dipeptide prosequence in
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human cathepsin G and elastase has been demonstrated by 
biosynthetic radio-labeling and radio-sequencing techniques 
(Salvesen and Enghild, 1990). The "pro" peptide is possibly 
removed during the packaging of the enzyme. The similarity 
between the potential preprosequences among these enzymes 
indicates that they may share a common activation mechanism.
The mature active enzyme of mouse chymase I consists of 
226 amino acids with a calculated Mr. of 25.4 kdr identical 
to that of dog chymase and MMCP-1 but two amino acids longer 
than MMCP-2. Sequence analysis reveals that mouse chymase I 
contains many characteristic features of a chymotrypsin-like 
enzyme, including the Ile-Ile-Gly-Gly amino terminal 
sequence and the residues comprising the catalytic "charge- 
relay" system (His, Asp and Ser) with their highly conserved 
adjacent sequences.
An interesting feature of mouse chymase I is that an 
Asn residue occurs in position 189 of the substrate binding 
pocket, rather than a Ser which is typically present in the 
substrate binding site of chymotryptic enzymes with 
substrate preferences for aromatic amino acids in the Pt 
position. In the corresponding position of MMCP-1 and 
RMCP—II Thr and Ala were found, respectively, Asn at 
position 189 has not been previously identified in another 
serine protease. Asn molecule is larger than Ser, and 
contains a terminal amide group rather than a hydroxyl 
group. How such substitution affects substrate preferences
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of the chymases enzyme is unknown. However, it has been 
shown that mutant trypsin with Ser189 or Lys189 has an altered 
substrate specificity and catalytic efficiency (Graf et al., 
1988).
Moreover, the size of the substrate binding pocket of 
mouse chymase I differs from those found in pancreatic 
chymotrypsin and trypsin, and most of the mast cell granule- 
associated proteases. The size of the pocket is related to 
residues 216 and 226 which form the neck of the binding 
pocket. Gly residues are present at these positions in both 
chymotrypsin and trypsin. This small amino acid permits the 
pockets to accommodate large aromatic amino acids in 
chymotrypsin, or Arg and Lys residues in trypsin. This 
feature is conserved in both mouse tryptase I and II (see 
Figure 26). However, Gly216 is replaced by a much bulkier 
residue Val in mouse chymase I. A similar substitution at 
this position is also found in MMCP II. Gly226 is replaced 
by a sightly larger residue Ala in mouse chymase I, which is 
consistent with other mast cell chymases (see Figure 29). 
These changes in mouse chymase I presumably will make the 
substrate binding pocket much smaller. The combined effects 
of the alterations of ‘the substrate binding pocket of mouse 
chymase I require biochemical characterization of the 
purified enzyme. However, very low chymotryptic activity 
was found in the lysate of these cells as assayed with 
common synthetic chymotrypsin substrates, suggesting that
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the typical chymotryptic substrate-binding specificity is 
altered. A better substrate and purification of the enzyme 
may be required for testing and measuring whether mouse 
chymase I truly has an unusual substrate specificity. Mouse 
chymase I is a basic protein with a net charge of +13 at 
neutral pH, which is comparable to dog chymase (+16) and 
RMCP I (+18). In contrast, the MMC-derived RMCP II and 
MMCP-1 have net charges of +3 and +4 at physiological pH.
The derived partial amino acid sequence of mouse 
chymase II consists of 175 amino acids with a novel COOH- 
terminal. It starts at the position corresponding to 
residue 50 of mouse chymase I and contains active site 
residues Asp and Ser. A Ser residue occurs in the 
substrate-binding pocket in agreement with a chymotryptic 
specificity. One of the major differences between the two 
mouse chymase primary structures is that chymase I contains 
only one potential glycosylation site (Asn59), whereas 
chymase II has at least two such sequences (Asn82 and Asn100) .
A sequence comparison between mouse chymases I and II 
with that of other chymases and bovine chymotrypsin is shown 
in Figure 27. Surprisingly, mouse chymases I and II only 
share 52% sequence identity, with 54% and 57% sequence 
homology to MMCP-I, respectively. This contrasts with the 
two tryptases cloned from these cells which shared 70% 
sequence identity. Mouse chymase I has its highest sequence 
similarity (72%) to dog chymase, suggesting that they may be
Figure 29. Primary structure alignments between the active 
enzyme portions of the mouse chymases, other known chymases, 
and bovine chymotrypsin. The residue numbering follows the 
standard chymotrypsinogen notation. A single small dot 
represents an identical amino acid residue at that position 
to that of mouse chymase I; gaps are introduced as dashes in 
order to achieve the maximal homology, stars indicate the 
active site residues His57, Asp102, and Ser195 which compose 
the catalytic triad. The putative N-linked glycosylation 
sites are underlined and its Asn is marked with a dot. The'**' 
number of residues in each enzyme are listed at the COOH end 
of its sequence. Identity percentages relative to each 
mouse tryptase are given in parentheses. The sources of the 
sequence data are as follow: mouse chymases I and II (this 
study), MMCP I (Le Trong et al., 1989), MMCP II (Serafin et 
al., 1990), RMCP I (Le Trong et al., 1987), RMCP II (Benfey 
et al., 1987), dog chymase (caughey et al., 1990), and 
bovine chymotrypsin (Blow et al., 1969).
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analogues In different species. Mouse chymase II has its 
highest homology (68%) with MMCP-II in the corresponding 
region.
There are seven cysteine residues located in mouse 
chymase I. Six of them occur at the identical position as 
in other known chymases and six of the nine cystienes of 
chymotrypsin. These may form disulfide bridges in the same 
pattern as in chymotrypsin, suggesting a conservation of the 
general tertiary structure among this enzyme superfamily. 
However, analysis of the three-dimensional structure of RMCP 
II, revealed a lack of the one disulfide bond near the 
active site seryl residue (Cys'l9t to cys*220 in chymotrypsin). 
This unique structural feature of the mast cell chymases may 
account for their distinctive substrate preferences (Le 
Trong, 1989).
Genomic Structure of Mouse Protease Genes
The mammalian serine protease superfamily is believed
to be derived from a common ancestor by gene duplication
during divergent evolution. The finding of an intron in
both mouse tryptase and chymase in the position
corresponding to a known intron in this gene superfamily
*
suggests that the conserved organization and structure of 
the serine protease gene family extends to the mouse serine 
protease gene(s).
The mouse DNA Southern blot analysis revealed that only 
one genomic DNA restriction enzyme fragment hybridized to
, . 1X3
mouse tryptase I- or II-specific probes regardless of which 
enzyme was used to digest the genomic DNA. This result 
indicates that both probes hybridize to only a single locus 
in the mouse genome, suggesting that there is only one mouse 
gene for each mast cell tryptase. Mouse tryptases I and II 
seem to be encoded by different genes. These are located at 
separate loci because each tryptase gene-specific probe 
displayed a distinct hybridization pattern. A similar 
result was observed with rat chymases RMCP I and II which 
are encoded by separate genes (Benfey et al., 1987).
Distribution and Expression of Tryptase and Chvmase 
in Mouse Mast Cells
Although mast cell differentiation and development is 
not fully understood, two different types of mast cells have 
been noted in mammalian species (reviewed in Stevens et al., 
1986). Rat and human mast cell subpopulations carry 
different combinations of proteases. In rat, CTMC and MMC 
contain the distinct chymases RMCP I and RMCP II, 
respectively (Woodbury et al., 1978). Rat connective tissue 
mast cells also contain tryptase (Kido et al., 1985), but 
structural variants of this rat enzyme are not known. In 
humans both TC and T mast cell types contain tryptase, 
whereas only the TC mast cells contain detectable amounts of 
chymase (Irani et al., 1986).
The expression pattern of serine proteases in different 
subpopulations of mouse mast cells seems much more
complicated than in the rat and human. To date, six 
different serine proteases have been identified in mouse 
mast cells. However, their distribution in MMC and CTMC is 
still unknown. Two chymases, MMCP-1 and MMCP-2, were well 
characterized and shown to be selectively expressed in 
different MMC populations (Serafin et al., 1990; Le Trong et 
al., 1989}. In addition, three distinct chymases (MMCP-3, 
MMCP-4 and MMCP-5) and a putative tryptase (MMCP-6) were 
identified in mouse serosal mast cells, representatives of 
CTMC, and their amino terminal sequences were determined 
(Reynolds et al., 1990). By comparing their limited amino- 
terminal amino acid sequences with that derived from our 
tryptase and chymase clones, it seems likely that mouse 
tryptase I is identical to MMCP-6, and mouse chymase I is 
the analogue of MMCP-5. Since mouse chymase II lacks the 
amino-terminal sequence, it remains to be determined whether 
mouse chymase II is a novel protease of mouse mast cells.
In contrast, mouse tryptase II has not been previously 
described. Thus, different mouse mast cell subpopulations 
can express at least seven distinct serine proteases in 
different combinations.
Both MMCP-6 (mouse tryptase I) and MMCP-5 (mouse 
chymase I) are granular constituents of mouse CTMC (Reynolds 
et al., 1990). This is consistent with our Northern blot 
hybridization results since both tryptase and chymase 
expressions were detected in mouse tongue. Tongue tissue
has been a good source of rat CTMC for enzyme purifications 
(Kido et al., 1984). In contrast, a barely detectable level 
of chymase was observed in the intestine which contains 
mainly MMC. The relationship of the two cloned mouse mast 
cell tryptases and the two cloned chymases to particular 
mast cell types can not be addressed at present. It is 
possible that a well-differentiated mast cell line can 
express proteases of both CTMC and MMC, The Kirsten sarcoma 
virus-immortalized mast cell line contained three of the 
CTMC- and one MMC-derived serine proteases (Reynolds et al., 
1990). Unfortunately, the in vivo-differentiated mouse MMC 
has not been successfully purified; no direct comparison 
between these culture- and in vivo-derlved mast cells has 
been possible. Mast cell studies still largely rely on 
immunohistochemical techniques which may limit our knowledge 
of mast cell diversity.
The two mouse tryptases appear to be expressed at a 
high level in the ABFTL-6 mast cell line, based on 0.5% 
positive plagues in the cDNA library and the isolation of 
four clones for each tryptase type. At present, we can only 
speculate concerning the finding of two different tryptases 
in ABFTL-6 mast cells* The cloning of the two enzymes in an 
apparently equal ratio suggests that mouse tryptase I and 
mouse tryptase II may comprise different subunits of an 
active tryptase tetramer, as for human tryptase (Schwartz et 
al., 1981a; Smith et al., 1984). A second possibility is
that the ABFTL-6 mast cells might be stuck at an 
intermediate stage in mast cell differentiation, displaying 
phenotypes of both immature and mature MMC. Another 
possibility is that viral transformation has resulted in the 
expression of tryptases representative of mucosal and 
connective tissue mast cells. Finally, both mouse tryptases 
may have diverged from a common ancestor during evolution 
for carrying out different biological functions. 
Clarification of these issues will reguire additional 
studies including the isolation and characterization of each 
active enzyme.
The structural information presented provides a sound 
basis for future work on these clearly different mouse 
tryptases and will aid in our understanding of mast cell 
function.
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Buffers and Solutions
Alkaline lysis solution
0.2 N NaOH, 1% SDS {make fresh)
Antibody solution
Tris-Saline containing 0.05% Tween-20, 1% BSA
Bradford reagent
0.01% (w/v) Coomassie Brilliant Blue G-250, 4.7% 
ethanol, and 8.5% phosphoric acid
CIA
chloroform/isoamyl alcohol (24:1 v/v)
GTC buffer
5.5 M GTC, 25 mM sodium citrate, 0.5% sodium 
lauryl sarcosine, pH 7.0, add B-mercaptoethanol 
to 0.2 M immediately prior to use
Kinasing buffer
40 mM Tris-HCl pH 7.6, 20 mM MgCl2, 10 mM DTT,
0.2 mM spermidine, loo /ig/ml BSA, 0.2 mM EDTA
LB broth
10 g bactotryptone, 5 g bacto-yeast extract, 5 g 
NaCl, add dH20 to 1 liter, autoclave to 
sterilize
Ligation buffer
50 rnM Tris-HCl pH 7.4, 10 mM MgClj, 10 mM DTT,
0.5 mM ATP, 0.1 mg/ml BSA
Loading Buffer
20 mM Tris-HCl pH 7.6, 0.5 M LiCl, 1 mM EDTA,
0.1 % sodium lauryl sarcosinate
M9 salt (10 X)
60 g NajHPOj, 30 g KHjHPO.,, 50 g NaCl, 100 g 
NH4C1, add dHjO to 1 liter, autoclave to 
sterilize
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Minimal medium
100 ml 10 X M9 salt, 10 ml 20% glucose, 0.1 ml 
1% thiamine solution, 1.0 ml 0.1 M CaCl1# 2.0 ml 
1 M MgS04, add dH20 to 1 liter
NZY broth
5 g NaCl, 2 g MgS04, 5 g yeast extract, 10 g NZ 
Amine (Casein hydrolysate), add dH20 to l liter, 
autoclave to sterilize
PEG solution
27% PEG (W/V) 8000 in 3.3 M NaCl
PBS
0.14 M NaCl, 50 mM sodium phosphate, pH 7.4
Prehybridization solution
3 X SSC (or SSPE), 10 mM Tris-HCl (pH 7.4), 1% 
dried non-fat milk, 0.1% SDS, 50% formamide
Protein sample buffer (8 ml)
4.7 ml dHjO, 1.0 ml 0.5 M Tris-HCl pH 6.8, 1.0 
ml glycerol, 1.0 ml 10% SDS, 0.1 ml B- 
mercaptoethanol, 0.2 ml 0.05% bromophenol blue
Protein staining solution
500 ml 95% ethanol, 100 ml acetic acid, 400 ml 
HjO, and 2.0 g Coomassie brilliant blue, add dHjO 
to 1 liter
RNclS6 A
20,000 U/ml in 10 mM Tris-HCl pH 7.5, 15 mM 
NaCl, boiled for 15 minutes 
#
Seguenase buffer
40 mM Tris-HCl pH 7.5, 20 mM MgCl2/ 50 mM NaCl.
Sequencing stop buffer
80% deionized formamide, 10 mM NaOH, 1 mM EDTA 
0.1% xylene cyanol, 0.1% bromophenol blue
SET solution
20% sucrose, 50 mM Tris-HCl pH 8.0, 50 mM EDTA
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SM buffer
20 mM Tris-HCl pH 7.4, 10 mM MgS04, 100 mM NaCl, 
0.01% gelatin
SOG loading buffer
60% sucrose, 0.1% Orange G
SSC (IX) 
SSPE (IX)
Ti0E,
T,E,1* 0.1
TAE
TB broth
THE
TBS
0.15 M NaCl, 15 mM sodium citrate, pH 7.0 
0.18 M NaCl, 10 mM NaP04, 1 mM EDTA, pH 7.7 
10 mM Tris-HCl pH 8.4, 1 mM EDTA 
1 mM Tris-HCl pH 8.4, 0.1 mM EDTA 
50 mM Tris pH 8.4, 40 mM acetic acid, 1 mM EDTA
5 g NaCl, 10 g Bactotryptone, add dH20 to 1 
liter, autoclave to sterilize
50 mM Tris pH 8.3, 50 mM boric acid, 1.25 mM 
EDTA
50 mM Tris-HCl pH 8.0, 150 mM NaCl
APPENDIX B
Restriction Enzymes, Recognition Sequences and Buffers
Enzyme Cleavage Restriction Endonuclease Buffer*’1
EcoRX GAATTC 100 Mm Tris-HCl, pH 7.2, 50 mM NaCl, 5 mM MgCl2
Hinfl GAANTC 6 mM Tris-HCl, pH 7.5, 50 mM NaCl, 6 mM MgCl2
Pstl CTGCAG 20 mM Tris-HCl, pH 7.4, 10 mM MgClj, 50 mM(NH4)S04
Not I GCGGCCGC 3 mM Tris-HCl, pH 7.4, 150 mM NaCl, 6 mM MgCl2
Dr a I TTTAAA 6 mM Tris-HCl, pH 7.6, 50 mM NaCl, 6 mM MgCl2
BamHI GGATCC 20 mM Tris-HCl, pH 7.4, 100 mM NaCl, 7 mM MgCl2
Sau3AI GATC 10 mM Tris-HCl, pH 7.5, 100 mM NaCl, 7 mM MgCl2
Kpnl GGTACC 6 mM Tris-HCl, pH 7.5, 6 mM NaCl, 6 mM MgCl2
HindiII AAGCTT 50 mM Tris-HCl, pH 8.0, 50 mM NaCl, 10 mM MgCl2
*A11 restriction digestion mixtures contained 6 mM B-Mercaptoethanol and 100 /ig/ml 
acetylated BSA (nuclease free).
bLSS restriction enzyme buffer: 20 mM Tris-HCl pH 7.4, 0.05 mM spermine, 0.125 mM
spermidine, 20 mM KCl, 70 mM NaCl, 10 mM MgCl2 (This buffer was used for multi-digestion 
reactions since it works for many enzymes including EcoRI, BamHI, Hinfl, Mbol, Hindlll, 
Kpnl, HaelX, Haelll, Mspl, TaqI, Rsal, Sau3A, Sail, Smal, and SacI).
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